
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4341594/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years. Cardiovascular Revascularization Medicine, 2022, 38, 106-110.	0.8	11
2	Impact of Left Ventricular Outflow Tract Calcification on Outcomes Following Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2022, 35, 1-7.	0.8	6
3	Non-Culprit MACE Rate in LRP: The Influence of Optimal Medical Therapy Using DAPT and Statins. Cardiovascular Revascularization Medicine, 2022, 37, 92-96.	0.8	2
4	Predicting future left anterior descending artery events from non-culprit lesions: insights from the Lipid-Rich Plaque study. European Heart Journal Cardiovascular Imaging, 2022, 23, 1365-1372.	1.2	2
5	Prosthetic valve endocarditis after transcatheter aortic valve replacement in <scp>lowâ€risk</scp> patients. Catheterization and Cardiovascular Interventions, 2022, 99, 896-903.	1.7	4
6	Longitudinal Distribution of Lipid-Rich Plaque in Nonculprit Lesions. JACC: Cardiovascular Imaging, 2022, 15, 168-170.	5.3	1
7	Transhepatic Access: Alternative Approach for Right Heart Catheterization and Pulmonary Angiography. Cardiovascular Revascularization Medicine, 2022, 40, 159-161.	0.8	1
8	Impact of Left Ventricular Outflow Tract Calcium on Hemodynamics and Outcomes in Patients After Transcatheter Aortic Valve Implantation With a Contemporary Self-Expanding Valve. American Journal of Cardiology, 2022, 168, 128-134.	1.6	1
9	Exploiting the Transformation Temperature to Reform an Infolded Nitinol Self-Expanding Peripheral Stent. Journal of Endovascular Therapy, 2022, , 152660282110687.	1.5	0
10	Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. Catheterization and Cardiovascular Interventions, 2022, 99, 1789-1795.	1.7	3
11	Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart – portable extracorporeal heart perfusion and monitoring system. American Heart Journal, 2022, 247, 90-99.	2.7	6
12	Coronary Artery Bypass at a Drug-Eluting Resorbable Magnesium Scaffold Site in a Porcine Model. Cardiovascular Revascularization Medicine, 2022, 42, 109-113.	0.8	2
13	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. Clinical Research in Cardiology, 2022, 111, 795-805.	3.3	8
14	Postoperative myocardial injury and outcomes in liver and kidney transplant patients. Cardiovascular Revascularization Medicine, 2022, , .	0.8	6
15	TAVR for Low-Risk Bicuspid AorticÂStenosis. JACC: Cardiovascular Interventions, 2022, 15, 533-535.	2.9	3
16	Vascular Closure: the ABC's. Current Cardiology Reports, 2022, 24, 355-364.	2.9	3
17	Near-infrared spectroscopy predicts events in men and women: Results from the Lipid Rich Plaque study. IJC Heart and Vasculature, 2022, 39, 100985.	1.1	0
18	Implications of COVID-19 Vaccination on Hospital Encounters and Outcomes. American Journal of Cardiology, 2022, 170, 105-111.	1.6	3

#	Article	IF	CITATIONS
19	The Need for Additional Phenotyping When Defining Cardiogenic Shock. JACC: Cardiovascular Interventions, 2022, 15, 890-895.	2.9	1
20	High-definition intravascular ultrasound: current clinical uses. International Journal of Cardiovascular Imaging, 2022, 38, 1213-1220.	0.6	4
21	Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nature Reviews Cardiology, 2022, 19, 684-703.	13.7	106
22	A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE). EuroIntervention, 2022, 18, e132-e139.	3.2	1
23	Lipid-rich plaque density and low-density lipoprotein cholesterol in statin-treated versus statin-naïve patients: a post hoc analysis of the LRP study. EuroIntervention, 2022, 18, 91-93.	3.2	2
24	Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study. EuroIntervention, 2022, 18, e407-e416.	3.2	15
25	Clinical Experience of the PK Papyrus Covered Stent in Patients With Coronary Artery Perforations: Results From a Multi-Center Humanitarian Device Exemption Survey. Cardiovascular Revascularization Medicine, 2022, 43, 97-101.	0.8	7
26	Optical coherence tomography assessment of acute thrombogenicity at bifurcation sites using different stenting techniques: A porcine arteriovenous shunt study. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0
27	Sex Disparities in Hemodynamics and Outcomes in Patients Who Underwent Contemporary Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 174, 101-106.	1.6	3
28	Incidence and Outcomes of Gastrointestinal Bleeding in Patients With Percutaneous Mechanical Circulatory Support Devices. American Journal of Cardiology, 2022, 174, 76-83.	1.6	2
29	Review of Late-Breaking Trials From CRT 2022. Cardiovascular Revascularization Medicine, 2022, 40, 3-7.	0.8	1
30	Cangrelor Use Patterns and Transition to Oral P2Y ₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. Journal of the American Heart Association, 2022, 11, .	3.7	4
31	Usefulness of Temporary Pacing in Patients With New Left Bundle Branch Block During Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, , .	1.6	0
32	Impact of left ventricular outflow tract calcium on valve geometry in selfâ€expanding transcatheter aorticâ€valve replacement. Catheterization and Cardiovascular Interventions, 2022, 100, 404-412.	1.7	1
33	Correlation between lipidic content and arterial-wall plaque burden: A lipid rich plaque study sub-analysis. International Journal of Cardiology, 2022, , .	1.7	0
34	Small Vessel Coronary Artery Disease: Rationale for Standardized Definition and Critical Appraisal of the Literature. , 2022, 1, 100403.		3
35	Treatment of a Heavily Calcified Celiac Artery Ostial Subtotal Occlusion Using Shockwave Lithotripsy: A Novel Approach. Cardiovascular Revascularization Medicine, 2021, 25, 72-74.	0.8	3
36	Anatomical Characteristics Associated With Hypoattenuated Leaflet Thickening in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2021, 27, 1-6.	0.8	14

#	Article	IF	CITATIONS
37	Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database. Cardiovascular Revascularization Medicine, 2021, 27, 57-62.	0.8	4
38	Review of PCR e-Course 2020 Late-Breaking Clinical Trials. Cardiovascular Revascularization Medicine, 2021, 27, 67-70.	0.8	0
39	Review of Structural Late-Breaking Trials From the TVT Connect 2020 and PCR e-Course 2020 Virtual Meetings. Cardiovascular Revascularization Medicine, 2021, 27, 71-78.	0.8	2
40	Colossal left main to right atrium fistula ligation complicated by left circumflex STEMI. Catheterization and Cardiovascular Interventions, 2021, 97, 1218-1220.	1.7	1
41	Micropuncture technique for femoral access is associated with lower vascular complications compared to standard needle. Catheterization and Cardiovascular Interventions, 2021, 97, 1379-1385.	1.7	28
42	Detachment of an EluNIR Drug-Eluting Stent Spring Tip. Cardiovascular Revascularization Medicine, 2021, 27, 98-99.	0.8	0
43	Intravascular ultrasound guidance in the evaluation and treatment of left main coronary artery disease. International Journal of Cardiology, 2021, 325, 168-175.	1.7	8
44	Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2021, 26, 1-5.	0.8	4
45	Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. American Journal of Cardiology, 2021, 142, 44-51.	1.6	1
46	Optical Coherence Tomography based treatment approach for patients with Acute Coronary Syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 141-149.	1.5	1
47	Cases of Early, Aggressive In-Stent Restenosis in Left Main Double Kissing (DK) Crush Technique and Treatment Options. Cardiovascular Revascularization Medicine, 2021, 27, 90-94.	0.8	0
48	Reply: Transcatheter Aortic Valve Implantation During COVID-19 Pandemic: The Device Also Matters. Cardiovascular Revascularization Medicine, 2021, 26, 68.	0.8	0
49	What Will 2021 Be Like?. Cardiovascular Revascularization Medicine, 2021, 22, 1-2.	0.8	0
50	The STRIATE-G Technique for COVID-19ÂST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2021, 14, 345-346.	2.9	2
51	National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016. American Heart Journal, 2021, 231, 25-31.	2.7	8
52	Return of the Left Internal Mammary Artery. Cardiovascular Revascularization Medicine, 2021, 23, 119-120.	0.8	0
53	LAMPOON techniques to prevent or manage left ventricular outflow tract obstruction in transcatheter mitral valve replacement. Annals of Cardiothoracic Surgery, 2021, 10, 172-179.	1.7	16
54	Right transradial coronary angiography in the setting of tortuous brachiocephalic/thoracic aorta ("elephant headâ€): Impact on fluoroscopy time and contrast use. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1

#	Article	IF	CITATIONS
55	Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients. Circulation: Cardiovascular Interventions, 2021, 14, e009983.	3.9	33
56	<scp>Realâ€world</scp> experience of <scp>sutureâ€based</scp> closure devices: Insights from the <scp>FDA</scp> Manufacturer and User Facility Device Experience. Catheterization and Cardiovascular Interventions, 2021, 98, 572-577.	1.7	11
57	Rescue alcohol septal ablation for dynamic left ventricular outflow tract obstruction and haemodynamic collapse after transcatheter aortic valve implantation. European Heart Journal, 2021, 42, 2955.	2.2	0
58	Near-Infrared Spectroscopy Intravascular Ultrasound Imaging Evaluation in Patients With Chronic Renal Insufficiency. JACC: Cardiovascular Imaging, 2021, 14, 1476-1478.	5.3	1
59	The vulnerable plaque detected: time to consider treatment. Lancet, The, 2021, 397, 943-945.	13.7	2
60	Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19. Cardiovascular Revascularization Medicine, 2021, 33, 41-44.	0.8	11
61	Overview of the virtual 2020 FDA' s circulatory system devices advisory panel on Neovasc reducer system. Catheterization and Cardiovascular Interventions, 2021, 98, 1152-1158.	1.7	2
62	Comparison of Characteristics and Outcomes of Patients With Acute Myocardial Infarction With Versus Without Coronarvirus-19. American Journal of Cardiology, 2021, 144, 8-12.	1.6	25
63	Pericardiocentesis induced right ventricular changes in patients with and without pulmonary hypertension. Echocardiography, 2021, 38, 752-759.	0.9	2
64	Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings. JACC: Cardiovascular Interventions, 2021, 14, 846-858.	2.9	33
65	Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2021, 14, 859-872.	2.9	44
66	Balloon-Expandable Valve Geometry After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Bicuspid Versus Tricuspid Aortic Stenosis. Cardiovascular Revascularization Medicine, 2021, 33, 7-12.	0.8	7
67	A patient-level, pooled analysis of mortality rates with the Passeo-18 Lux paclitaxel drug-coated balloon in peripheral arterial disease. Cardiovascular Revascularization Medicine, 2021, 33, 49-54.	0.8	1
68	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. Journal of the American College of Cardiology, 2021, 77, 1994-2003.	2.8	96
69	The impact of COVID-19 patients with troponin elevation on renal impairment and clinical outcome. Cardiovascular Revascularization Medicine, 2021, 33, 45-48.	0.8	1
70	<scp>Propensityâ€matched</scp> comparison of <scp>largeâ€bore</scp> access closure in transcatheter aortic valve replacement using <scp>MANTA</scp> versus Perclose: A <scp>realâ€world</scp> experience. Catheterization and Cardiovascular Interventions, 2021, 98, 580-585.	1.7	11
71	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	2.2	80
72	Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 941-948.	2.9	55

#	Article	IF	CITATIONS
73	BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction. Circulation: Cardiovascular Interventions, 2021, 14, e010238.	3.9	34
74	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. American Heart Journal, 2021, 235, 140-148.	2.7	14
75	Catheter Selection and Angiographic Views for Anomalous Coronary Arteries. JACC: Cardiovascular Interventions, 2021, 14, 995-1008.	2.9	14
76	Reasons for Screen Failure for Transcatheter Mitral Valve Repair and Replacement. American Journal of Cardiology, 2021, 148, 130-137.	1.6	12
77	Comparison of Quantitative Flow Ratio and Invasive Physiology Indices in a Diverse Population at a Tertiary United States Hospital. Cardiovascular Revascularization Medicine, 2021, 32, 1-4.	0.8	4
78	Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. Cardiovascular Revascularization Medicine, 2021, 33, 62-67.	0.8	11
79	Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newerâ€Generation Drugâ€Eluting Stents. Journal of the American Heart Association, 2021, 10, e019815.	3.7	14
80	Overview of the Virtual 2021 FDA's Circulatory System Devices Advisory Panel on Lutonix 014 Drug-Coated Percutaneous Transluminal Angioplasty Catheter for Below-the-Knee Lesions in Critical Limb Ischemia. Cardiovascular Revascularization Medicine, 2021, 33, 55-61.	0.8	3
81	High bleeding risk patients: one size does not fit all. EuroIntervention, 2021, 17, 189-191.	3.2	Ο
82	Pre-Operative Cardiovascular Testing before Liver Transplantation. American Journal of Cardiology, 2021, 152, 132-137.	1.6	3
83	The Impact of Aortic Angulation on Contemporary Transcatheter Aortic Valve Replacement Outcomes. JACC: Cardiovascular Interventions, 2021, 14, 1209-1215.	2.9	7
84	Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support. Circulation: Cardiovascular Interventions, 2021, 14, e009960.	3.9	10
85	Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 149, 57-63.	1.6	0
86	Real-World Experience of the MANTA Closure Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. Cardiovascular Revascularization Medicine, 2021, 27, 63-66.	0.8	5
87	Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients: Meta-Analysis. Cardiovascular Revascularization Medicine, 2021, 33, 1-6.	0.8	6
88	Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-Risk Patients With Severe Aortic Stenosis. JACC: Cardiovascular Interventions, 2021, 14, 1169-1180.	2.9	30
89	One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery. American Journal of Cardiology, 2021, 151, 45-50.	1.6	3
90	Review of Imaging and Physiology Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 71-75.	0.8	0

#	Article	IF	CITATIONS
91	Review of Structural Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 76-81.	0.8	0
92	Transcatheter aortic valve replacement in low-risk patients: 2-year results from the LRT trial. American Heart Journal, 2021, 237, 25-33.	2.7	7
93	Treatment of Left Main Disease: Let the Patient Choose. Journal of the American Heart Association, 2021, 10, e021990.	3.7	3
94	Review of Late-Breaking Trials From CRT 2021 Virtual. Cardiovascular Revascularization Medicine, 2021, 28, 3-8.	0.8	0
95	Review of Coronary Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 65-70.	0.8	0
96	Percutaneous Management of a Saphenous Vein Graft Aneurysm With GraftMaster Covered Stents. Cardiovascular Revascularization Medicine, 2021, 28, 147-149.	0.8	0
97	Frequency of Lipid-Rich Coronary Plaques in Stable Angina Pectoris versus Acute Coronary Syndrome (from the Lipid Rich Plaque Study). American Journal of Cardiology, 2021, 158, 1-5.	1.6	1
98	Comparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis. American Journal of Cardiology, 2021, 160, 106-111.	1.6	4
99	Complications of Late-Presenting Myocardial Infarction in a COVID-19 Patient. Cardiovascular Revascularization Medicine, 2021, 29, 100-101.	0.8	Ο
100	Effect of Procedural Technique on Cardiovascular Outcomes Following Second-Generation Drug-Eluting Resorbable Magnesium Scaffold Implantation. Cardiovascular Revascularization Medicine, 2021, 29, 1-6.	0.8	9
101	High-Risk Percutaneous Coronary Intervention of Native Coronary Arteries Without Mechanical Circulatory Support in Acute Coronary Syndrome Without Cardiogenic Shock. American Journal of Cardiology, 2021, 158, 37-44.	1.6	1
102	Single-Center Experience With the LOTUS Edge Transcatheter Heart Valve. Cardiovascular Revascularization Medicine, 2021, 29, 85-88.	0.8	3
103	Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. American Heart Journal, 2021, 238, 59-65.	2.7	2
104	Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack. American Journal of Cardiology, 2021, 153, 129-134.	1.6	5
105	Review of Interventional Late Breaking Trials From AHA Scientific Sessions 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 29, 71-76.	0.8	Ο
106	Implications of Left Ventricular Function on Short-Term Outcomes in COVID-19 Patients With Myocardial Injury. Cardiovascular Revascularization Medicine, 2021, 29, 45-49.	0.8	5
107	Impact of Endothelial Shear Stress on Absorption Process of Resorbable Magnesium Scaffold: A BIOSOLVE-II Substudy. Cardiovascular Revascularization Medicine, 2021, 29, 9-15.	0.8	6
108	Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy. European Heart Journal Cardiovascular Imaging, 2021, , .	1.2	1

#	Article	IF	CITATIONS
109	Contemporary postâ€marketing adverse events and modes of failure related to VASCADE Vascular Closure System: The utility of the MAUDE database. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	3
110	Unprotected Left Main Percutaneous Coronary Intervention With or Without Hemodynamic Support. American Journal of Cardiology, 2021, 154, 29-32.	1.6	1
111	Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 2228-2230.	2.9	2
112	Response by Khalid et al to Letter Regarding Article, "Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support― Circulation: Cardiovascular Interventions, 2021, 14, e011275.	3.9	1
113	Lipid-rich plaques detected by near-infrared spectroscopy predict coronary events irrespective of age: A Lipid Rich Plaque sub-study. Atherosclerosis, 2021, 334, 17-22.	0.8	3
114	Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. American Journal of Cardiology, 2021, 157, 42-47.	1.6	5
115	Impact of intravascular ultrasound on Outcomes following PErcutaneous coronary interventioN for In-stent Restenosis (iOPEN-ISR study). International Journal of Cardiology, 2021, 340, 17-21.	1.7	12
116	Valve-in-Valve for Failing Mitral Bioprosthesis With Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2021, 16, 409-413.	0.9	2
117	Outcomes After Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Anatomy. JACC: Cardiovascular Interventions, 2021, 14, 2144-2155.	2.9	37
118	Comparison of plaque distribution and wire-free functional assessment in patients with stable angina and non-ST elevation myocardial infarction: an optical coherence tomography and quantitative flow ratio study. Coronary Artery Disease, 2021, 32, 131-137.	0.7	2
119	The new normal, CRT 2022, Colin Powell, and CRM journal growth. Cardiovascular Revascularization Medicine, 2021, 34, 1-2.	0.8	0
120	Scaffold thrombosis: what is to blame?. EuroIntervention, 2021, 17, e955-e957.	3.2	0
121	Impact of baseline imaging of non-culprit coronary lesions and adverse events: Insight from LRP study. Cardiovascular Revascularization Medicine, 2021, , .	0.8	1
122	Feasibility of a Porcine Arteriovenous Shunt Model for Assessment of Acute Thrombogenicity in Bifurcation Stenting Technique By Optical Coherence Tomography. Cardiovascular Revascularization Medicine, 2020, 21, 1000-1005.	0.8	2
123	Comparison of quantitative flow ratio value of left anterior descending and circumflex coronary artery in patients with Takotsubo syndrome. International Journal of Cardiovascular Imaging, 2020, 36, 3-8.	1.5	3
124	Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. Cardiovascular Revascularization Medicine, 2020, 21, 127-136.	0.8	13
125	Impact of Baseline Left Ventricular Diastolic Dysfunction in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 258-263.	1.6	5
126	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. American Heart Journal, 2020, 219, 1-8.	2.7	27

#	Article	IF	CITATIONS
127	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12†months: Pooled patient level analysis from BIOSOLVE II–III and BIOFLOW II trials. International Journal of Cardiology, 2020, 300, 60-65.	1.7	13
128	Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies. Cardiovascular Revascularization Medicine, 2020, 21, 251-253.	0.8	0
129	Should Non-ST-Elevation Myocardial Infarction be Treated like ST-Elevation Myocardial Infarction With Shorter Door-to-Balloon Time?. American Journal of Cardiology, 2020, 125, 165-168.	1.6	7
130	Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis. American Journal of Cardiology, 2020, 125, 712-719.	1.6	5
131	Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality. American Heart Journal, 2020, 222, 112-120.	2.7	19
132	mpact of Intravascular Ultrasound on utcomes Following rcutaneous Coronary Interventio in Complex Lesions (iOPEN Complex). American Heart Journal, 2020, 221, 74-83.	2.7	28
133	Apple Watch detecting high-grade block after transcatheter aortic valve implantation. European Heart Journal, 2020, 41, 1096-1096.	2.2	9
134	Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for Patient- and Circuit-Related Adverse Events Involving Extracorporeal Membrane Oxygenation. Cardiovascular Revascularization Medicine, 2020, 21, 230-234.	0.8	11
135	Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2020, 109, 1789-1796.	1.3	2
136	Real-World Experience of the Sentinel Cerebral Protection Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. Cardiovascular Revascularization Medicine, 2020, 21, 235-238.	0.8	14
137	Impact of periprocedural biomarker elevation on mortality in stable angina pectoris patients undergoing elective coronary intervention: a systematic review and meta-analysis including 24 666 patients. Coronary Artery Disease, 2020, 31, 137-146.	0.7	5
138	Time-to-Event Meta-Analysis - Time to Do it Right!. Cardiovascular Revascularization Medicine, 2020, 21, 692-693.	0.8	0
139	Procedural Outcomes of Patients Undergoing Percutaneous Coronary Intervention for De Novo Lesions in the Ostial and Proximal Left Circumflex Coronary Artery. American Journal of Cardiology, 2020, 135, 62-67.	1.6	9
140	Intravascular Lithotripsy for Treatment of Severely Calcified CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2020, 76, 2635-2646.	2.8	209
141	COVID-19: Leave politics out of practicing medicine. Cardiovascular Revascularization Medicine, 2020, 21, 937-938.	0.8	4
142	The Story is Not Yet "COMPLETE― Cardiovascular Revascularization Medicine, 2020, 21, 807.	0.8	0
143	Letter by Khalid et al Regarding Article, "The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support― Circulation, 2020, 142, e76-e77.	1.6	0
144	One Valve Type Does Not Fit All. Cardiovascular Revascularization Medicine, 2020, 21, 931.	0.8	0

#	Article	IF	CITATIONS
145	Impact of Transcatheter Aortic Valve Replacement on Risk Profiles of Surgical Aortic Valve Replacement Patients. Cardiovascular Revascularization Medicine, 2020, 21, 959-963.	0.8	3
146	Self-Expanding Transcatheter Aortic Valve–Frame Infolding. JACC: Cardiovascular Interventions, 2020, 13, 789-790.	2.9	8
147	Safety Profile of an Intra-Annular Self-Expanding Transcatheter AorticÂValve and Next-Generation Low-Profile Delivery System. JACC: Cardiovascular Interventions, 2020, 13, 2467-2478.	2.9	27
148	The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale. American Heart Journal, 2020, 228, 65-71.	2.7	25
149	Reply. JACC: Cardiovascular Interventions, 2020, 13, 1834.	2.9	0
150	Concertina Effect: Incorporating Intravascular Imaging to Aid in Diagnosis. Cardiovascular Revascularization Medicine, 2020, 21, 1323-1324.	0.8	0
151	Clinical Implications of Physical Function and Resilience in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of the American Heart Association, 2020, 9, e017075.	3.7	11
152	In-Stent Restenosis. Journal of the American College of Cardiology, 2020, 76, 1389-1390.	2.8	6
153	The DAEDALUS Study. Journal of the American College of Cardiology, 2020, 76, 1390-1391.	2.8	Ο
154	Trends and Outcomes of Restenosis AfterÂCoronary Stent Implantation inÂtheÂUnited States. Journal of the American College of Cardiology, 2020, 76, 1521-1531.	2.8	106
155	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. Circulation: Cardiovascular Interventions, 2020, 13, e009189.	3.9	11
156	Risk of Coronary Obstruction and Feasibility of Coronary Access After Repeat Transcatheter Aortic Valve Replacement With the Self-Expanding Evolut Valve. Circulation: Cardiovascular Interventions, 2020, 13, e009496.	3.9	38
157	Cardiac safety research consortium "shock Il―think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97.	2.7	14
158	Procedural Characteristics and Outcomes of Patients Undergoing Percutaneous Coronary Intervention During Normal Work Hours Versus Non-work Hours. American Journal of Cardiology, 2020, 135, 32-39.	1.6	1
159	Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 3062-3064.	2.8	5
160	Sutureless SAVR Versus TAVR for Symptomatic Severe Aortic Stenosis. JACC: Cardiovascular Interventions, 2020, 13, 2655-2657.	2.9	2
161	Admissions Rate and Timing of Revascularization in the United States in Patients With Non-ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 134, 24-31.	1.6	17
162	Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 135, 154-165.	1.6	7

#	Article	IF	CITATIONS
163	Review of CRT 2020 Late-breaking Trials. Cardiovascular Revascularization Medicine, 2020, 21, 707-711.	0.8	1
164	MitraClip 30-Day Readmissions and Impact of Early Discharge: An Analysis from the Nationwide Readmissions Database 2016. Cardiovascular Revascularization Medicine, 2020, 21, 954-958.	0.8	7
165	Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization. JACC: Cardiovascular Interventions, 2020, 13, 1343-1353.	2.9	68
166	Tip-to-Base LAMPOON to Prevent LeftÂVentricular Outflow Tract Obstruction in Valve-in-Valve Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1126-1128.	2.9	12
167	Treatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic. Cardiovascular Revascularization Medicine, 2020, 21, 1024-1029.	0.8	20
168	Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention. Cardiovascular Revascularization Medicine, 2020, 21, 1041-1052.	0.8	7
169	Review of ACC 2020 Late-Breaking Trials in Interventional Cardiology. Cardiovascular Revascularization Medicine, 2020, 21, 905-911.	0.8	1
170	Guidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic. Cardiovascular Revascularization Medicine, 2020, 21, 1030-1033.	0.8	11
171	Swedish Coronary Angiography and Angioplasty Registry Scare on Drug-Coated Balloons. JACC: Cardiovascular Interventions, 2020, 13, 1379.	2.9	0
172	New Year and New Journal: Resolutions for 2020. Cardiovascular Revascularization Medicine, 2020, 21, 1.	0.8	0
173	Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. Lancet, The, 2020, 396, 669-683.	13.7	76
174	Intravascular Lithotripsy Facilitated Percutaneous Endovascular Intervention of the Aortic Arch: A Single-Center Experience. Cardiovascular Revascularization Medicine, 2020, 21, 1006-1015.	0.8	9
175	Near-Infrared Spectroscopy Intravascular Ultrasound Imaging: State of the Art. Frontiers in Cardiovascular Medicine, 2020, 7, 107.	2.4	17
176	Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment. Cardiovascular Revascularization Medicine, 2020, 21, 700-701.	0.8	1
177	Association of Right Ventricular Longitudinal Strain with Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of the American Society of Echocardiography, 2020, 33, 452-460.	2.8	34
178	Coronary Artery Disease Assessed by Computed Tomography-Based Leaman Score in Patients With Low-Risk Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 1216-1221.	1.6	5
179	Drug-Coated Balloon for DeÂNovoÂCoronary Artery Disease. Journal of the American College of Cardiology, 2020, 75, 1061-1073.	2.8	96
180	Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Bicuspid Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2020, 13, 1019-1027.	2.9	77

#	Article	IF	CITATIONS
181	The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence. Cardiovascular Revascularization Medicine, 2020, 21, 540-548.	0.8	11
182	Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease. Cardiovascular Revascularization Medicine, 2020, 21, 549-555.	0.8	0
183	Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk. American Journal of Cardiology, 2020, 125, 1631-1637.	1.6	9
184	Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial. Clinical Therapeutics, 2020, 42, 649-660.e9.	2.5	12
185	Supporting evidence from optical coherence tomography for shortening dual antiplatelet therapy after drug-eluting stents implantation. Expert Review of Cardiovascular Therapy, 2020, 18, 261-267.	1.5	3
186	Coronary Heart Disease: Have We Reached a Plateau in Primary Prevention?. Journal of the American Heart Association, 2020, 9, e04963.	3.7	10
187	CRT 2020, COVID-19 and Beyond. Cardiovascular Revascularization Medicine, 2020, 21, 705-706.	0.8	0
188	Percutaneous transcatheter release of stuck mechanical mitral valve leaflet. European Heart Journal, 2020, 41, 4072-4072.	2.2	5
189	Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years. Cardiovascular Revascularization Medicine, 2020, 21, 1150-1154.	0.8	21
190	Feasibility of Coronary Access and AorticÂValve Reintervention in Low-Risk TAVR Patients. JACC: Cardiovascular Interventions, 2020, 13, 726-735.	2.9	83
191	COVID-19 (SARS-CoV-2) and the Heart $\hat{a} \in$ " An Ominous Association. Cardiovascular Revascularization Medicine, 2020, 21, 946-949.	0.8	41
192	Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS) Tj ETQq0 0 (of the BIOSOLVE-II first-in-man trial. EuroIntervention, 2020, 15, e1375-e1382.) rgBT /Ov 3.2	erlock 10 Tf 5 29
193	Adverse events with orbital atherectomy: an analytic review of the MAUDE database. EuroIntervention, 2020, 16, e325-e327.	3.2	15
194	Bioresorbable scaffolds: did we jump the gun?. EuroIntervention, 2020, 16, e103-e105.	3.2	2
195	Bioresorbable Scaffolds: Current Technology and Future Perspectives. Rambam Maimonides Medical Journal, 2020, 11, e0016.	1.0	19
196	NIRS-IVUS. JACC: Cardiovascular Imaging, 2020, 14, 1451-1453.	5.3	0
197	Abstract 16624: Gender Disparities Based on Time to Revascularization in the Treatment of Non-st-segment Elevation Myocardial Infarction: An Analysis of 748,439 Nstemi Admissions. Circulation, 2020, 142, .	1.6	0
198	Abstract 16040: High-risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support in Acute Coronary Syndrome. Circulation, 2020, 142, .	1.6	0

#	Article	IF	CITATIONS
199	Abstract 16677: Real World Screen Failure Rates for Transcatheter Mitral Valve Repair and Replacement for Mitral Regurgitation. Circulation, 2020, 142, .	1.6	0
200	Abstract 14527: Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, .	1.6	1
201	Abstract 17148: Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis: Two-Year Results From the LRT Trial. Circulation, 2020, 142, .	1.6	0
202	Abstract 16860: Racial Disparity in COVID-19 Patients With Concomitant Myocardial Injury. Circulation, 2020, 142, .	1.6	0
203	Deoxyribonucleic Acid Repair Activity Is Associated with Healed Coronary Plaque Rupture by Optical Coherence Tomography. Journal of Cardiovascular Translational Research, 2019, 12, 608-610.	2.4	1
204	Restenosis of Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007023.	3.9	158
205	Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device. Circulation: Cardiovascular Interventions, 2019, 12, e007258.	3.9	87
206	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. American Journal of Cardiology, 2019, 124, 1020-1026.	1.6	11
207	Kissing Intravascular Lithotripsy Facilitated Endovascular Repair of a Complex Saccular Abdominal Aortic Aneurysm With Narrowed Distal Aorta. JACC: Cardiovascular Interventions, 2019, 12, e97-e99.	2.9	8
208	Valve-in-Valve TAVR: State-of-the-Art Review. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2019, 14, 299-310.	0.9	40
209	Impact of two formulas to calculate percentage diameter stenosis of coronary lesions: from stenosis models (phantom lesion model) to actual clinical lesions. International Journal of Cardiovascular Imaging, 2019, 35, 2139-2146.	1.5	3
210	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
211	The BASILICA Trial. JACC: Cardiovascular Interventions, 2019, 12, 1240-1252.	2.9	183
212	Trends in Death Rate 2009 to 2018 Following Percutaneous Coronary Intervention Stratified by Acuteness of Presentation. American Journal of Cardiology, 2019, 124, 1349-1356.	1.6	7
213	Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet, The, 2019, 394, 1629-1637.	13.7	263
214	Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses. Circulation: Cardiovascular Interventions, 2019, 12, e008155.	3.9	26
215	Relation of Sex and Race to Outcomes in Patients Undergoing Percutaneous Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2019, 123, 913-918.	1.6	14
216	Pacemaker Implantation and Dependency After Transcatheter Aortic Valve Replacement in the REPRISE III Trial. Journal of the American Heart Association, 2019, 8, e012594.	3.7	48

#	Article	IF	CITATIONS
217	Intravascular Ultrasound Assessment of the Impact of Intravascular Lithotripsy. Cardiovascular Revascularization Medicine, 2019, 20, 1209-1210.	0.8	3
218	Predictors of 90-Day Readmission and in-Hospital Mortality in Takotsubo Cardiomyopathy: An Analysis of 28,079 Index Admissions. Cardiovascular Revascularization Medicine, 2019, 20, 973-979.	0.8	16
219	Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1228-1238.	1.6	1
220	Impact of calcification on percutaneous coronary intervention: MACEâ€Trial 1â€year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	1.7	36
221	Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography ― Review and Meta-Analysis ―. Circulation Journal, 2019, 83, 1480-1488.	1.6	22
222	OCT-Guided Treatment of Calcified Coronary Artery Disease: Breaking the Barrier to Stent Expansion. Current Cardiovascular Imaging Reports, 2019, 12, 1.	0.6	7
223	Letter by Khalid et al Regarding Article, "Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment–Elevation Myocardial Infarction: A Pilot Study Using the Impella CPâ€ Circulation, 2019, 139, e1040-e1041.	1.6	11
224	Blinding results for transcatheter mitral valve repair. Cardiovascular Revascularization Medicine, 2019, 20, 530.	0.8	1
225	Pulmonary cyclone: a case of large pulmonary arteriovenous malformation causing paradoxical coronary embolus treated with percutaneous closure device. European Heart Journal, 2019, 40, 1941-1941.	2.2	0
226	Expanding the Treatment of Calcified Lesions. Cardiovascular Revascularization Medicine, 2019, 20, 622-623.	0.8	1
227	Left Bundle Branch Block After TAVR. JACC: Cardiovascular Interventions, 2019, 12, 1185-1187.	2.9	3
228	TAVR in Low-Risk Patients. JACC: Cardiovascular Interventions, 2019, 12, 901-907.	2.9	65
229	Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine, 2019, 20, 624-625.	0.8	1
230	Usefulness of Longitudinal Strain to Assess Remodeling of Right and Left Cardiac Chambers Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 124, 253-261.	1.6	10
231	The Guardian Will Alert You Soon. Journal of the American College of Cardiology, 2019, 73, 1928-1930.	2.8	0
232	Pre-Operative Cardiovascular Testing and Post-Renal Transplant Clinical Outcomes. Cardiovascular Revascularization Medicine, 2019, 20, 588-593.	0.8	8
233	Adverse events and modes of failure related to the FilterWire EZ Embolic Protection System: Lessons learned from an analytic review of the FDA MAUDE database. Catheterization and Cardiovascular Interventions, 2019, 94, 157-164.	1.7	12
234	Usefulness of skeletal muscle area detected by computed tomography to predict mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis study. International Journal of Cardiovascular Imaging, 2019, 35, 1141-1147.	1.5	25

#	Article	IF	CITATIONS
235	Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy. American Journal of Cardiology, 2019, 123, 1878-1883.	1.6	4
236	Techniques to Optimize the Use of Optical Coherence Tomography: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database. Cardiovascular Revascularization Medicine, 2019, 20, 507-512.	0.8	14
237	Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis and Prior External Chest Radiation. Cardiovascular Revascularization Medicine, 2019, 20, 376-380.	0.8	10
238	Adverse Events and Modes of Failure Related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database. Cardiovascular Revascularization Medicine, 2019, 20, 503-506.	0.8	29
239	CRM: The Next Milestone. Cardiovascular Revascularization Medicine, 2019, 20, 1.	0.8	0
240	Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanical vs Self-expanding Valves. JAMA Cardiology, 2019, 4, 223.	6.1	42
241	Adverse Events Associated with the Use of Guide Extension Catheters during Percutaneous Coronary Intervention: Reports from the Manufacturer and User Facility Device Experience (MAUDE) database. Cardiovascular Revascularization Medicine, 2019, 20, 409-412.	0.8	29
242	First Report of Edge Vascular Response at 12†Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study. Cardiovascular Revascularization Medicine, 2019, 20, 392-398.	0.8	9
243	Reproducibility of Semi-automated Three-dimensional Volumetric Analysis using Cardiac Computed Tomography in Patients With Left Ventricular Assist Device. Cardiovascular Revascularization Medicine, 2019, 20, 381-386.	0.8	1
244	Racial Disparities in Clinical Characteristics and Outcomes of Women Undergoing Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine, 2019, 20, 1039-1042.	0.8	11
245	Dedicated Closure Device for Transcaval Access Closure. JACC: Cardiovascular Interventions, 2019, 12, 2198-2206.	2.9	9
246	Hemodynamics and Subclinical Leaflet Thrombosis in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Imaging, 2019, 12, e009608.	2.6	31
247	Safety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension. Cardiovascular Revascularization Medicine, 2019, 20, 1090-1095.	0.8	5
248	Was 2019 a Very Good Year?. Cardiovascular Revascularization Medicine, 2019, 20, 1037-1038.	0.8	0
249	Takotsubo syndrome: State-of-the-art review by an expert panel – Part 1. Cardiovascular Revascularization Medicine, 2019, 20, 70-79.	0.8	71
250	Takotsubo syndrome: State-of-the-art review by an expert panel – Part 2. Cardiovascular Revascularization Medicine, 2019, 20, 153-166.	0.8	42
251	Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis. European Heart Journal Cardiovascular Imaging, 2019. 20. 916-924.	1.2	13
252	Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial). American Journal of Cardiology, 2019, 123, 1044-1051.	1.6	1

#	Article	IF	CITATIONS
253	A word of caution using selfâ€expanding transcatheter aortic valveâ€frame infolding. Catheterization and Cardiovascular Interventions, 2019, 93, 555-558.	1.7	9
254	Spontaneous dissections involving multiple coronary arteries and a vertebral artery over 7 years. European Heart Journal, 2019, 40, 322-322.	2.2	2
255	Role of contractile reserve as a predictor of mortality in lowâ€flow, lowâ€gradient severe aortic stenosis following transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2019, 93, 707-712.	1.7	12
256	Comparison of coronary revascularization appropriateness for nonâ€acute coronary syndrome cases under the 2017 update vs the 2012 appropriate use criteria. Catheterization and Cardiovascular Interventions, 2019, 93, 620-625.	1.7	0
257	Coronary perfusion pressure and left ventricular hemodynamics as predictors of cardiovascular collapse following percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2019, 20, 11-15.	0.8	5
258	Intravascular ultrasound-guided drug-eluting stent implantation. Minerva Cardioangiologica, 2019, 67, 306-317.	1.2	13
259	Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database. EuroIntervention, 2019, 15, 44-46.	3.2	24
260	BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. EuroIntervention, 2019, 15, e1006-e1013.	3.2	35
261	Reply to the letter to the editor "Impella device use in high-risk PCI― EuroIntervention, 2019, 15, 732-732.	3.2	2
262	Impact of Balloon Predilatation on Hemodynamics and Outcomes After Transcatheter Aortic Valve Implantation With the Self-Expanding CoreValve Prosthesis. American Journal of Cardiology, 2018, 121, 1358-1364.	1.6	3
263	Utility of Invasive Electrophysiology Studies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 121, 1351-1357.	1.6	40
264	Left main true bifurcation PCI: In the aftermath of DKCRUSH V trial: The case for modifying Medina terminology to include complexity of LMCA anatomy. Cardiovascular Revascularization Medicine, 2018, 19, 137-138.	0.8	1
265	1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. Journal of the American College of Cardiology, 2018, 71, 1841-1853.	2.8	288
266	Reduction of catheter kinks and knots via radial approach. Catheterization and Cardiovascular Interventions, 2018, 92, 1141-1146.	1.7	14
267	MynxGrip® vascular closure device versus manual compression for hemostasis of percutaneous transfemoral venous access closure: Results from a prospective multicenter randomized study. Cardiovascular Revascularization Medicine, 2018, 19, 418-422.	0.8	14
268	Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI – State-of-the-art review. International Journal of Cardiology, 2018, 264, 39-44.	1.7	2
269	Comparison of the Efficacy and Safety of Orbital and Rotational Atherectomy in Calcified Narrowings in Patients Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 121, 934-939.	1.6	14
270	Utility of an additive frailty tests index score for mortality risk assessment following transcatheter aortic valve replacement. American Heart Journal, 2018, 200, 11-16.	2.7	17

#	Article	IF	CITATIONS
271	Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Progress in Cardiovascular Diseases, 2018, 60, 500-507.	3.1	14
272	In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial. International Journal of Cardiology, 2018, 255, 22-28.	1.7	54
273	Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis. JAMA - Journal of the American Medical Association, 2018, 319, 27.	7.4	135
274	Laser-Assisted Transcaval Access for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, e3-e4.	2.9	4
275	Clinical Frailty as an Outcome Predictor After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 121, 850-855.	1.6	43
276	Comparison of treatment strategies for femoroâ€popliteal disease: A network metaâ€analysis. Catheterization and Cardiovascular Interventions, 2018, 91, 1320-1328.	1.7	17
277	Temporal trends in patient referral for Transcatheter aortic valve replacement and reasons for exclusion at a high-volume Center in the United States. American Heart Journal, 2018, 196, 74-81.	2.7	4
278	Successful transcatheter aortic valve replacement in an oversized 800†mm2 annulus and bicuspid aortic valve. Cardiovascular Revascularization Medicine, 2018, 19, 65-67.	0.8	3
279	In-Stent Restenosis of Drug-Eluting Stents Compared With a Matched Group of Patients With De Novo Coronary Artery Stenosis. American Journal of Cardiology, 2018, 121, 1512-1518.	1.6	19
280	Bioresorbable polymer drug-eluting stents – Authors' reply. Lancet, The, 2018, 391, 936-937.	13.7	0
281	Bioprosthesis leaflet thrombosis following self-expanding valve-in-valve transcatheter aortic valve replacement in patient taking factor Xa inhibitor and warfarin: A case report. Cardiovascular Revascularization Medicine, 2018, 19, 29-32.	0.8	1
282	An amber signal lights up before the red: do not dismiss it. European Heart Journal, 2018, 39, 303-304.	2.2	2
283	Intraprocedural invasive hemodynamic parameters as predictors of short- and long-term outcomes in patients undergoing transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2018, 19, 257-262.	0.8	3
284	Patient characteristics in variable left ventricular recovery from Takotsubo syndrome. Cardiovascular Revascularization Medicine, 2018, 19, 247-250.	0.8	1
285	Intravascular ultrasound assessment of the effect of laser energy on the arterial wall during the treatment of femoro-popliteal lesions: a CliRpath excimer laser system to enlarge lumen openings (CELLO) registry study. International Journal of Cardiovascular Imaging, 2018, 34, 345-352.	1.5	10
286	Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis. International Journal of Cardiovascular Imaging, 2018, 34, 503-513.	1.5	30
287	A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine, 2018, 19, 5-11.	0.8	18
288	Cardiogenic Shock Complicating Transcatheter Aortic Valve Replacement Due to Severe Para-Valvular Regurgitation. Cardiovascular Revascularization Medicine, 2018, 19, 393-395.	0.8	2

#	Article	IF	CITATIONS
289	TCT-707 A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 3 Year Clinical Results. Journal of the American College of Cardiology, 2018, 72, B283.	2.8	1
290	Emergent valve-in-valve transcatheter aortic valve replacement in patient with acute aortic regurgitation and cardiogenic shock with preoperative extracorporeal membrane oxygenator: A case report and review of the literature. Cardiovascular Revascularization Medicine, 2018, 19, 68-70.	0.8	9
291	Summary of the 2018 Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2018, 19, 964-970.	0.8	6
292	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. Journal of the American College of Cardiology, 2018, 72, 3287-3297.	2.8	73
293	The Power of Imaging. JACC: Cardiovascular Interventions, 2018, 11, 2232-2233.	2.9	1
294	The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome. Cardiovascular Revascularization Medicine, 2018, 19, 912-916.	0.8	5
295	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circulation: Cardiovascular Interventions, 2018, 11, e007331.	3.9	23
296	Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis. Journal of the American College of Cardiology, 2018, 72, 2095-2105.	2.8	175
297	Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach. Current Cardiology Reports, 2018, 20, 140.	2.9	14
298	Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery. American Journal of Cardiology, 2018, 122, 1652-1660.	1.6	53
299	Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. American Journal of Cardiology, 2018, 122, 1536-1540.	1.6	0
300	Accuracy of predicted orthogonal projection angles for valve deployment during transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2018, 12, 398-403.	1.3	6
301	Clinical outcomes of complete revascularization using either angiography-guided or fractional flow reserve-guided drug-eluting stent implantation in non-culprit vessels in ST elevation myocardial infarction patients: insights from a study based on a systematic review and meta-analysis. International lournal of Cardiovascular Imaging, 2018, 34, 1349-1364.	1.5	6
302	Transcatheter Aortic Valve Replacement in Intermediate―and Lowâ€Risk Patients. Journal of the American Heart Association, 2018, 7, .	3.7	19
303	Left Main Revascularization. JACC: Cardiovascular Interventions, 2018, 11, 1244-1246.	2.9	3
304	Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12â€month outcomes of <scp>BIOSOLVEâ€II</scp> and <scp>BIOSOLVEâ€II</scp> . Catheterization and Cardiovascular Interventions, 2018, 92, E502-E511.	1.7	48
305	Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine, 2018, 19, 971-975.	0.8	10
306	Predicted magnitude of alternate access in the contemporary transcatheter aortic valve replacement era. Catheterization and Cardiovascular Interventions, 2018, 92, 964-971.	1.7	12

#	Article	IF	CITATIONS
307	Stentless strategy in primary PCI setting: An alternative strategy in some clinical scenarios?. Cardiovascular Revascularization Medicine, 2018, 19, 5-7.	0.8	2
308	Letter by Dan et al Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial― Circulation: Cardiovascular Interventions, 2018, 11, e006679.	3.9	4
309	Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds. EuroIntervention, 2018, 14, e1040-e1048.	3.2	36
310	Impact of triggering event in outcomes of stress-induced (Takotsubo) cardiomyopathy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 280-286.	1.0	43
311	Choice of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Impacts Hemodynamics Differently According to Aortic Annular Size. American Journal of Cardiology, 2017, 119, 900-904.	1.6	41
312	Cangrelor With and Without GlycoproteinÂllb/IIIa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47
313	The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale. American Heart Journal, 2017, 192, 98-104.	2.7	44
314	Intravenously Delivered Mesenchymal Stem Cells. Circulation Research, 2017, 120, 1598-1613.	4.5	142
315	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. American Journal of Cardiology, 2017, 119, 1135-1140.	1.6	5
316	Comparison of Propensity Score–Matched Analysis of Acute Kidney Injury After Percutaneous Coronary Intervention With Transradial Versus Transfemoral Approaches. American Journal of Cardiology, 2017, 119, 1507-1511.	1.6	11
317	Comparison of Baseline Characteristics and Inhospital Outcomes of Patients and Use of Bare Metal Versus Drug-Eluting Stents During Percutaneous Coronary Intervention 2005 to 2015 at a Single Tertiary Hospital. American Journal of Cardiology, 2017, 119, 1324-1330.	1.6	4
318	Contemporary transcatheter aortic valve replacement with thirdâ€generation balloonâ€expandable versus selfâ€expanding devices. Journal of Interventional Cardiology, 2017, 30, 356-361.	1.2	40
319	Use of an ePTFE-covered nitinol self-expanding stent graft for the treatment off pre-closure device failure during transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2017, 18, 128-132.	0.8	15
320	Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 1131-1133.	2.9	4
321	Correlates and Significance of Elevation of Cardiac Biomarkers Elevation Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 850-856.	1.6	9
322	CRT 2017 late-breaking trials. Cardiovascular Revascularization Medicine, 2017, 18, 304-307.	0.8	1
323	FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices. Cardiovascular Revascularization Medicine, 2017, 18, 308-311.	0.8	0
324	Does the new generation of drug-eluting stents render bare metal stents obsolete?. Cardiovascular Revascularization Medicine, 2017, 18, 456-461.	0.8	11

#	Article	IF	CITATIONS
325	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	3.7	30
326	Feasibility of transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis: Rationale and design of the Low Risk TAVR (LRT) study. American Heart Journal, 2017, 189, 103-109.	2.7	24
327	ANTARCTIC: platelet function testing to adjust therapy. Lancet, The, 2017, 389, 1192-1193.	13.7	0
328	Outcome of implantation of a second selfâ€expanding valve for the treatment of residual significant aortic regurgitation. Catheterization and Cardiovascular Interventions, 2017, 90, 673-679.	1.7	1
329	Labeling Stents/Scaffolds for Diabetes. JACC: Cardiovascular Interventions, 2017, 10, 50-52.	2.9	2
330	Assessing strategies to improve patient management. Nature Reviews Cardiology, 2017, 14, 77-78.	13.7	2
331	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor–Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
332	Management and Outcome of Residual Aortic Regurgitation After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 632-639.	1.6	3
333	CRT: A multichannel educational event. Cardiovascular Revascularization Medicine, 2017, 18, S1.	0.8	Ο
334	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet, The, 2017, 390, 1843-1852.	13.7	214
335	Pre-Transcatheter Aortic Valve Replacement Right Bundle Branch Block. JACC: Cardiovascular Interventions, 2017, 10, 1575-1577.	2.9	6
336	Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome. American Journal of Cardiology, 2017, 120, 1272-1278.	1.6	6
337	Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial. Cardiovascular Revascularization Medicine, 2017, 18, 475-481.	0.8	9
338	Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	83
339	The State of the Absorb BioresorbableÂScaffold. JACC: Cardiovascular Interventions, 2017, 10, 2349-2359.	2.9	55
340	Overview of the 2017 US Food and Drug Administration Circulatory System Devices Panel meeting on the Sentinel Cerebral Protection System. American Heart Journal, 2017, 192, 113-119.	2.7	12
341	High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. American Heart Journal, 2017, 192, 76-84.	2.7	3
342	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	2.8	405

#	Article	IF	CITATIONS
343	Society of Thoracic Surgeons Score Variance Results in Risk Reclassification of Patients Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2017, 2, 455.	6.1	22
344	Does direct stenting with drugâ€eluting stents improve outcome? A metaâ€analysis of 10,900 patients. Catheterization and Cardiovascular Interventions, 2017, 90, 213-222.	1.7	8
345	A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular Revascularization Medicine, 2017, 18, 79-85.	0.8	28
346	Overview of the 2016 US Food and Drug Administration Circulatory System Devices Panel Meeting on the Amplatzer Patent Foramen Ovale Occluder. American Journal of Cardiology, 2017, 119, 153-155.	1.6	2
347	Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS) Tj ETQq1	1 8:78431	.4 ₂ gBT /Ove
348	Comparison of transradial and transfemoral access in patients undergoing percutaneous coronary intervention for complex coronary lesions. Catheterization and Cardiovascular Interventions, 2017, 89, 640-646.	1.7	10
349	Impact of right ventricular function on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement. American Heart Journal, 2017, 184, 141-147.	2.7	35
350	Crowdsourcing, a novel platform to generate scientific manuscripts, now in cardiology. Cardiovascular Revascularization Medicine, 2017, 18, 555-556.	0.8	0
351	Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. American Heart Journal, 2017, 193, 35-45.	2.7	13
352	Diagnosis and management challenges of in-stent restenosis in coronary arteries. World Journal of Cardiology, 2017, 9, 640.	1.5	56
353	A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds. Cleveland Clinic Journal of Medicine, 2017, 84, e20-e24.	1.3	6
354	Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model. EuroIntervention, 2017, 13, 440-449.	3.2	55
355	Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention, 2017, 13, 432-439.	3.2	98
356	Body mass index association with survival in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2016, 88, 118-124.	1.7	43
357	Review: Stent fracture in the drug-eluting stent era. Cardiovascular Revascularization Medicine, 2016, 17, 404-411.	0.8	28
358	The influence of advancing age on implantation of drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2016, 88, 516-521.	1.7	9
359	The impact of prior stroke on the outcome of patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2016, 17, 322-327.	0.8	4
360	Impact of baseline mitral regurgitation on short- and long-term outcomes following transcatheter aortic valve replacement. American Heart Journal, 2016, 178, 19-27.	2.7	14

#	Article	IF	CITATIONS
361	Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with <i>de novo</i> coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. European Heart Journal, 2016, 37, 2701-2709.	2.2	149
362	Impact of transfemoral versus transapical access on mortality among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2016, 17, 318-321.	0.8	19
363	How should we manage thrombosis of Viabahn stent-graft? A case report focused on catheter-directed thrombolysis. Cardiovascular Revascularization Medicine, 2016, 17, 134-137.	0.8	1
364	Impact of Functional Versus Organic Baseline Mitral Regurgitation on Short- and Long-Term Outcomes After Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2016, 117, 839-846.	1.6	18
365	Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies. International Journal of Cardiology, 2016, 216, 133-139.	1.7	73
366	Role of CMR in TAVR. JACC: Cardiovascular Imaging, 2016, 9, 593-602.	5.3	24
367	Inflammation as a Driver of Adverse LeftÂVentricular Remodeling After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 2050-2060.	2.8	340
368	Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System. JACC: Cardiovascular Interventions, 2016, 9, 1757-1764.	2.9	24
369	Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	79
370	Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis. Cardiovascular Revascularization Medicine, 2016, 17, 535-545.	0.8	12
371	Comparison in Men Versus Women of Co-morbidities, Complications, and Outcomes After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2016, 118, 1692-1697.	1.6	17
372	Bioresorbable scaffolds are here, please handle with care. Cardiovascular Revascularization Medicine, 2016, 17, 353-354.	0.8	6
373	Drug oated Balloons: Seeking a Niche in the Treatment of Coronary Artery Disease. Journal of Interventional Cardiology, 2016, 29, 480-482.	1.2	Ο
374	Does the disparity in baseline characteristics of patients undergoing transcatheter aortic valve replacement with 23 mm vs. 26 mm valves impact clinical outcome?. Catheterization and Cardiovascular Interventions, 2016, 87, 176-182.	1.7	0
375	Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNERâ€I trial: Success and safety. Catheterization and Cardiovascular Interventions, 2016, 87, 165-175.	1.7	67
376	Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. Journal of Interventional Cardiology, 2016, 29, 108-112.	1.2	13
377	In-Stent Restenosis?. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	9
378	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	19

#	Article	IF	CITATIONS
379	The AngelMed Guardian system: Is there a role for implantable devices for early detection of coronary artery occlusion?. Cardiovascular Revascularization Medicine, 2016, 17, 522-527.	0.8	3
380	Intracoronary Brachytherapy for RecurrentÂDrug-Eluting Stent Failure. JACC: Cardiovascular Interventions, 2016, 9, 1259-1265.	2.9	56
381	Impact of restrictive versus obstructive pulmonary function patterns on mortality in patients undergoing transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2016, 17, 181-185.	0.8	6
382	A single center experience of Zilver PTX for femoro-popliteal lesions. Cardiovascular Revascularization Medicine, 2016, 17, 399-403.	0.8	5
383	Comparison of clinical outcomes with the utilization of monitored anesthesia care vs. general anesthesia in patients undergoing transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2016, 17, 384-390.	0.8	34
384	Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Versus the Balloon-Expandable SAPIEN XT Valve. American Journal of Cardiology, 2016, 117, 1502-1510.	1.6	6
385	Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: Technical performance, success, and safety. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 773-780.e14.	0.8	32
386	Ultrasound vs Angiography for Drug-Eluting Stent Implantation. JAMA - Journal of the American Medical Association, 2016, 315, 2469.	7.4	0
387	Multimodality imaging demonstrates trafficking of liposomes preferentially to ischemic myocardium. Cardiovascular Revascularization Medicine, 2016, 17, 106-112.	0.8	13
388	Trends in Complications and Outcomes ofÂPatients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 355-363.	2.9	72
389	Defining the <i>non-</i> vulnerable and vulnerable patients with computed tomography coronary angiography: evaluation of atherosclerotic plaque burden and composition. European Heart Journal Cardiovascular Imaging, 2016, 17, 481-491.	1.2	39
390	Learning curves for transfemoral transcatheter aortic valve replacement in the <scp>PARTNERâ€I</scp> trial: Technical performance. Catheterization and Cardiovascular Interventions, 2016, 87, 154-162.	1.7	61
391	Chemical Renal Denervation. JACC: Cardiovascular Interventions, 2016, 9, 599-601.	2.9	0
392	Vascular access in critical limb ischemia. Cardiovascular Revascularization Medicine, 2016, 17, 190-198.	0.8	11
393	Effects of Ticagrelor Versus Clopidogrel inÂTroponin-Negative Patients With Low-Risk ACS Undergoing AdÂHoc PCI. Journal of the American College of Cardiology, 2016, 67, 603-613.	2.8	41
394	Clinical profiles and correlates of mortality in nonagenarians with severe aortic stenosis undergoing transcatheter aortic valve replacement. American Heart Journal, 2016, 173, 118-125.	2.7	20
395	Embolic Protection Devices in Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, e003284.	3.9	12
396	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. International Journal of Cardiology, 2016, 205, 17-22.	1.7	28

#	Article	IF	CITATIONS
397	Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2016, 9, 12-24.	2.9	152
398	Frequency of Angina Pectoris After Percutaneous Coronary Intervention and the Effect of Metallic Stent Type. American Journal of Cardiology, 2016, 117, 526-531.	1.6	20
399	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal, 2016, 37, 536-545.	2.2	211
400	Cerebrovascular accidents after percutaneous coronary interventions from 2002 to 2014: Incidence, outcomes, and associated variables. American Heart Journal, 2016, 172, 80-87.	2.7	6
401	The influence of lipid-containing plaque composition assessed by near-infrared spectroscopy on coronary lesion remodelling. European Heart Journal Cardiovascular Imaging, 2016, 17, 821-831.	1.2	15
402	Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet, The, 2016, 387, 31-39.	13.7	284
403	The adjunctive use of Angio-Seal in femoral vascular closure following percutaneous transcatheter aortic valve replacement. EuroIntervention, 2016, 12, 88-93.	3.2	21
404	Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. EuroIntervention, 2016, 12, 828-833.	3.2	64
405	Chipping of calcified plaques by orbital atherectomy systems, but holding approval tight: is the FDA moving faster than the European CE agency? A North American perspective. EuroIntervention, 2016, 12, 1083-1086.	3.2	0
406	Contemporary Use of Veno-Arterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Acute Coronary Syndrome. Journal of Invasive Cardiology, 2016, 28, 52-7.	0.4	20
407	Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension, 2015, 9, 959-965.	2.3	3
408	Safety and longâ€ŧerm outcomes after percutaneous coronary intervention in patients with human immunodeficiency virus. Catheterization and Cardiovascular Interventions, 2015, 85, 192-198.	1.7	17
409	Outcome comparison of Africanâ€American and caucasian patients with severe aortic stenosis subjected to transcatheter aortic valve replacement: A singleâ€center experience. Catheterization and Cardiovascular Interventions, 2015, 85, 640-647.	1.7	31
410	Will TAVR Become the Default Treatment for Patients With Severe Aortic Stenosis?â^—. Journal of the American College of Cardiology, 2015, 66, 122-124.	2.8	8
411	Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2015, 115, 1435-1442.	1.6	50
412	Reply. American Journal of Cardiology, 2015, 116, 494-495.	1.6	0
413	Prevalence and predictors of left atrial thrombus in patients with atrial fibrillation: is transesophageal echocardiography necessary before cardioversion?. Cardiovascular Revascularization Medicine, 2015, 16, 12-14.	0.8	27
414	Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN Left Atrial Appendage Closure Therapy. American Journal of Cardiology, 2015, 115, 378-384.	1.6	39

#	Article	IF	CITATIONS
415	Delayed consent: will there be a shift in approach for US primary percutaneous coronary intervention trials?. Lancet, The, 2015, 386, 714-716.	13.7	3
416	Clinical outcomes of first- and second-generation drug-eluting stents in patients undergoing rotational atherectomy for heavily calcified coronary lesions. Cardiovascular Revascularization Medicine, 2015, 16, 147-150.	0.8	16
417	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. Heart, 2015, 101, 1309-1317.	2.9	40
418	Role of near-infrared spectroscopy in intravascular coronary imaging. Cardiovascular Revascularization Medicine, 2015, 16, 299-305.	0.8	14
419	Analysis of Long-Term Survival Following Transcatheter Aortic Valve Implantation from a Single High-Volume Center. American Journal of Cardiology, 2015, 116, 256-263.	1.6	17
420	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2015, 8, e002232.	3.9	18
421	Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis. Cardiovascular Revascularization Medicine, 2015, 16, 84-89.	0.8	3
422	Rational use of rotational atherectomy in calcified lesions in the drug-eluting stent era: Review of the evidence and current practice. Cardiovascular Revascularization Medicine, 2015, 16, 78-83.	0.8	20
423	Impact of Pre-Procedural Serum Albumin Levels on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2015, 115, 1260-1264.	1.6	38
424	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2015, 8, e001441.	3.9	172
425	Embolic Protection Device for Saphenous Vein Graft Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002371.	3.9	5
426	Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Cangrelor. American Journal of Cardiology, 2015, 115, 1154-1161.	1.6	11
427	Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. Cardiovascular Revascularization Medicine, 2015, 16, 151-155.	0.8	5
428	Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 585-596.	1.8	4
429	The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective. American Heart Journal, 2015, 170, 13-22.	2.7	9
430	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. American Journal of Cardiology, 2015, 115, 716-723.	1.6	30
431	Outcome of Left-Sided Cardiac Remodeling in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 595-603.	1.6	19
432	Comparison of clinical outcomes in patients presenting with an acute coronary syndrome due to stent thrombosis or saphenous vein graft occlusion and undergoing percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2015, 16, 441-446.	0.8	2

#	Article	IF	CITATIONS
433	Intracoronary imaging: see more, better or worse?: Table 1. European Heart Journal, 2015, 36, 3356-3358.	2.2	4
434	Radial versus femoral access in patients presenting with acute coronary syndrome in the post-matrix era: Still one size does not fit all. Cardiovascular Revascularization Medicine, 2015, 16, 435-436.	0.8	0
435	Comparison of Bleeding Outcomes After Percutaneous Coronary Intervention in Patients With Versus Without Aortic Stenosis. American Journal of Cardiology, 2015, 116, 1106-1109.	1.6	Ο
436	Response to Letter Regarding Article, "Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations― Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	0
437	Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2015, 85, 468-477.	1.7	40
438	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. American Heart Journal, 2015, 169, 6-16.e6.	2.7	89
439	Impact of Blood Transfusions on Short- and Long-Term Mortality in Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 115, 93-99.	1.6	26
440	Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. International Journal of Cardiology, 2015, 179, 225-227.	1.7	13
441	Laser Atheroablation in Challenging Coronary Lesions. , 2015, , 97-102.		2
442	In-stent restenosis: local drug delivery with a stent or balloon?. Journal of Thoracic Disease, 2015, 7, 1691-2.	1.4	2
443	Clinical impact of second-generation everolimus-eluting stents compared with first-generation drug-eluting stents in diabetic patients undergoing multivessel percutaneous coronary intervention. Journal of Invasive Cardiology, 2015, 27, 263-8.	0.4	2
444	Comparison of Rotational Atherectomy, Plain Old Balloon Angioplasty, and Cutting-Balloon Angioplasty Prior to Drug-Eluting Stent Implantation for the Treatment of Heavily Calcified Coronary Lesions. Journal of Invasive Cardiology, 2015, 27, 387-91.	0.4	11
445	Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2014, 15, 334-339.	0.8	Ο
446	Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. European Heart Journal, 2014, 35, 2663-2671.	2.2	71
447	Evaluation of the Edwards Lifesciences SAPIEN transcatheter heart valve. Expert Review of Medical Devices, 2014, 11, 553-562.	2.8	2
448	The Impact of Diabetes Mellitus on Longâ€Term Clinical Outcomes After Percutaneous Coronary Saphenous Vein Graft Interventions in the Drugâ€Eluting Stent Era. Journal of Interventional Cardiology, 2014, 27, 391-398.	1.2	6
449	Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. Circulation: Cardiovascular Interventions, 2014, 7, 768-776.	3.9	56
450	Transfer distance effect on reperfusion: timeline of ST-elevation patients transferred for primary percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2014, 15, 369-374.	0.8	3

#	ARTICLE	IF	CITATIONS
451	Drug-coated balloon for peripheral arterial disease in the United States: a safe and effective landing zone. Cardiovascular Revascularization Medicine, 2014, 15, 367-368.	0.8	0
452	Overview of the 2014 Food and Drug Administration Circulatory System Devices Panel meeting regarding the Lutonix® drug coated balloon. Cardiovascular Revascularization Medicine, 2014, 15, 402-407.	0.8	4
453	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA - Journal of the American Medical Association, 2014, 312, 162.	7.4	762
454	Longâ€ŧerm safety and efficacy of secondâ€generation everolimusâ€eluting stents compared to other limusâ€eluting stents and bare metal stents in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2014, 84, 1053-1060.	1.7	9
455	Editorial: Drugâ€Coated Balloon for Coronary Indications: Too Little, Too Late. Journal of Interventional Cardiology, 2014, 27, 580-581.	1.2	2
456	Aortic valve ChromaFlo®: A feasibility study of aortic regurgitation and effective annular aortic area assessment in a porcine model. Cardiovascular Revascularization Medicine, 2014, 15, 156-159.	0.8	2
457	The new FDA reality. Cardiovascular Revascularization Medicine, 2014, 15, 1-2.	0.8	9
458	C-reactive protein prior to percutaneous coronary intervention: Do we still need to check the lipid panel?. Cardiovascular Revascularization Medicine, 2014, 15, 129-130.	0.8	0
459	The impact of live case transmission on patient outcomes during transcatheter aortic valve replacement: Results from the VERITAS study. Cardiovascular Revascularization Medicine, 2014, 15, 63-68.	0.8	7
460	Use of emergency medical services expedites in-hospital care processes in patients presenting with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2014, 15, 219-225.	0.8	13
461	Stroke After Aortic Valve Replacement. Circulation, 2014, 129, 2245-2247.	1.6	9
462	Correlates for mortality in patients presented with acute myocardial infarct complicated by cardiogenic shock. Cardiovascular Revascularization Medicine, 2014, 15, 13-17.	0.8	3
463	The dynamics of the coronary collateral circulation. Nature Reviews Cardiology, 2014, 11, 191-197.	13.7	80
464	Outcomes of Patients With Chronic Lung Disease and Severe Aortic Stenosis Treated With Transcatheter Versus Surgical Aortic Valve Replacement or Standard Therapy. Journal of the American College of Cardiology, 2014, 63, 269-279.	2.8	99
465	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Diabetes and Severe Aortic Stenosis at High Risk for Surgery. Journal of the American College of Cardiology, 2014, 63, 1090-1099.	2.8	61
466	Editorial: Renal Sympathetic Denervation: A True Lack of Efficacy, or the Victim of a "Perfect Storm"?. Cardiovascular Revascularization Medicine, 2014, 15, 61-62.	0.8	3
467	Left Atrial Appendage Occlusion. Journal of the American College of Cardiology, 2014, 63, 291-298.	2.8	72
468	Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. Cardiovascular Revascularization Medicine, 2014, 15, 23-28.	0.8	8

RON WAKSMAN

#	Article	IF	CITATIONS
469	In vivo evaluation of axial integrity of coronary stents using intravascular ultrasound: Insights on longitudinal stent deformation. Catheterization and Cardiovascular Interventions, 2014, 84, 397-405.	1.7	10
470	Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine, 2014, 15, 315-322.	0.8	13
471	Correlates and Outcomes of Late and VeryÂLate Drug-Eluting Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1093-1102.	2.9	55
472	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31â€379 patients. Open Heart, 2014, 1, e000064.	2.3	88
473	Coronary Blood Flow in Patients With Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1264-1268.	1.6	21
474	Current application and bioavailability of drug-eluting stents. Expert Opinion on Drug Delivery, 2014, 11, 689-709.	5.0	7
475	Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1447-1455.	1.6	82
476	Superior survival with transcatheter core valve over surgery in high-risk patients with aortic stenosis: good news for the Heart Team. Cardiovascular Revascularization Medicine, 2014, 15, 191-192.	0.8	0
477	Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. American Heart Journal, 2014, 168, 545-551.	2.7	12
478	Definitions of Periprocedural Myocardial Infarction as Surrogates for Catheterization Laboratory Quality or Clinical Trial End Points. American Journal of Cardiology, 2014, 113, 1326-1330.	1.6	11
479	Relation of Preprocedural Assessment of Myocardial Contractility Reserve on Outcomes of Aortic Stenosis Patients With Impaired Left Ventricular Function Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 113, 1536-1542.	1.6	35
480	A Systematic Review and Collaborative Meta-Analysis to Determine the Incremental Value of Copeptin for Rapid Rule-Out of Acute Myocardial Infarction. American Journal of Cardiology, 2014, 113, 1581-1591.	1.6	118
481	Bioresorbable scaffolds: rationale, current status, challenges, and future. European Heart Journal, 2014, 35, 765-776.	2.2	228
482	Incidence and correlates of major bleeding after percutaneous coronary intervention across different clinical presentations. American Heart Journal, 2014, 168, 248-255.	2.7	18
483	The Effects of Novel, Bioresorbable Scaffolds on Coronary Vascular Pathophysiology. Journal of Cardiovascular Translational Research, 2014, 7, 413-425.	2.4	19
484	The Utility of Thrombus Aspiration for NSTEMI. Journal of the American College of Cardiology, 2014, 64, 1125-1127.	2.8	2
485	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 857-867.	2.9	223

Comparison of Outcomes After Percutaneous Coronary Intervention Among Different Coronary Subsets (Stable and Unstable Angina Pectoris and ST-Segment and Non-ST-Segment Myocardial) Tj ETQq0 0 0 rgBT1/Øverlock20 Tf 50 5 486

#	Article	IF	CITATIONS
487	Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2014, 113, 1968-1976.	1.6	19
488	Impact of Previous Coronary Artery Bypass Grafting on Patients Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis. American Journal of Cardiology, 2014, 113, 1222-1227.	1.6	24
489	Operator learning curve for transradial percutaneous coronary interventions: implications for the initiation of a transradial access program in contemporary US practice. Cardiovascular Revascularization Medicine, 2014, 15, 195-199.	0.8	21
490	Mortality in patients requiring pacemaker implantation following transcatheter aortic valve replacement: Insights from a systematic review and meta-analysis. International Journal of Cardiology, 2014, 174, 207-208.	1.7	14
491	Intra-stent tissue evaluation within bare metal and drug-eluting stents >3years since implantation in patients with mild to moderate neointimal proliferation using optical coherence tomography and virtual histology intravascular ultrasound. Cardiovascular Revascularization Medicine, 2014, 15, 149-155.	0.8	6
492	Drug-eluting stents in patients on chronic hemodialysis: Paclitaxel-eluting stents vs. limus-eluting stents. Cardiovascular Revascularization Medicine, 2014, 15, 86-91.	0.8	9
493	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis, 2014, 233, 224-231.	0.8	25
494	Real-time, two-way interaction during ST-segment elevation myocardial infarction management improves door-to-balloon times. Cardiovascular Revascularization Medicine, 2014, 15, 263-268.	0.8	1
495	Comparison of frequency and severity of longitudinal stent deformation among various drug-eluting stents: An intravascular ultrasound study. International Journal of Cardiology, 2014, 175, 261-267.	1.7	8
496	Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2014, 15, 278-283.	0.8	0
497	Design and rationale of the ANALYZE ST study: A prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. American Heart Journal, 2014, 168, 424-429.e1.	2.7	5
498	Serial 2-Dimensional and 3-Dimensional OpticalÂCoherence Tomography Assessment ofÂOverhanging Struts of Drug-Eluting Absorbable Metal Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 575-576.	2.9	3
499	Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. Atherosclerosis, 2014, 235, 295-298.	0.8	3
500	Bioresorbable metal scaffold for cardiovascular application: Current knowledge and future perspectives. Cardiovascular Revascularization Medicine, 2014, 15, 109-116.	0.8	39
501	Commercial Versus PARTNER Study Experience With the Transfemoral Edwards SAPIEN Valve for Inoperable Patients With Severe Aortic Stenosis. American Journal of Cardiology, 2014, 113, 342-347.	1.6	10
502	Optimal Intravascular Ultrasound Criteria for Defining the Functional Significance of Intermediate Coronary Stenosis: An International Multicenter Study. Cardiology, 2014, 127, 256-262.	1.4	27
503	Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Journal of Invasive Cardiology, 2014, 26, 154-60.	0.4	3
504	Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to transcatheter/surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2013, 82, 632-637.	1.7	66

#	Article	IF	CITATIONS
505	Safety and efficacy of everolimusâ€eluting stents versus paclitaxelâ€eluting stents in a diabetic population. Catheterization and Cardiovascular Interventions, 2013, 81, 759-765.	1.7	7
506	Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet, The, 2013, 381, 836-844.	13.7	343
507	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
508	Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. American Heart Journal, 2013, 166, 266-272.	2.7	31
509	The Conundrum of Thrombus Aspiration: The TAPAS TASTE Sour. Cardiovascular Revascularization Medicine, 2013, 14, 305-306.	0.8	3
510	Paravalvular regurgitation after transcatheter aortic valve replacement: Diagnosis, clinical outcome, preventive and therapeutic strategies. Cardiovascular Revascularization Medicine, 2013, 14, 174-181.	0.8	17
511	FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. Journal of the American College of Cardiology, 2013, 61, 917-923.	2.8	201
512	Sympathetic renal denervation: Hypertension beyond SYMPLICITY. Cardiovascular Revascularization Medicine, 2013, 14, 229-235.	0.8	13
513	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	2.8	807
514	In-stent restenosis of drug-eluting stents. Future Cardiology, 2013, 9, 721-731.	1.2	15
515	Second‫scp>Generation Everolimus‫scp>Eluting Stents Compared to First‫scp>Generation Drug‫scp>Eluting Stents in Patients Treated for Multivessel Disease. Journal of Interventional Cardiology, 2013, 26, 561-569.	1.2	4
516	Outcomes of concomitant percutaneous coronary intervention and balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2013, 82, E835-41.	1.7	22
517	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients with Nonâ€STâ€Segment Elevation Acute Coronary Syndrome Initially Treated with Fondaparinux: Results from an International, Multicenter, Randomized Pilot Study (SWITCH III). Journal of Interventional Cardiology, 2013, 26, 107-113.	1.2	28
518	IVUS-guided CTO-PCI. , 2013, , 67-77.		0
519	Asahi wires. , 2013, , 97-104.		Ο
520	A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population. International Journal of Cardiology, 2013, 170, 43-48.	1.7	6
521	Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity. Cardiovascular Revascularization Medicine, 2013, 14, 76-80.	0.8	3
522	Two-Year Follow-Up of Outcomes of Second-Generation Everolimus-Eluting Stents Versus First-Generation Drug-Eluting Stents for Stenosis of Saphenous Vein Grafts Used as Aortocoronary Conduits. American Journal of Cardiology, 2013, 112, 61-67.	1.6	29

#	Article	IF	CITATIONS
523	Graft-Free surgical retroperitoneal vascular access as bail-out technique for failed percutaneous approach to transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2013, 14, 23-26.	0.8	5
524	Innovation: A Key to Success in the Treatment of Cardiovascular Disease. Cardiovascular Revascularization Medicine, 2013, 14, 121.	0.8	1
525	Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). American Heart Journal, 2013, 166, 421-428.e1.	2.7	71
526	Outcome Improvement for STEMI Patients: The Next Breakthrough in Interventional Cardiology?. Cardiovascular Revascularization Medicine, 2013, 14, 1-2.	0.8	1
527	Safety and feasibility of performing staged non-culprit vessel percutaneous coronary intervention within the index hospitalization in patients with ST-segment elevation myocardial infarction and multivessel disease. Cardiovascular Revascularization Medicine, 2013, 14, 258-263.	0.8	2
528	Radial access as a default for PCI: too early to call. Lancet, The, 2013, 382, 841-842.	13.7	3
529	Clinical Outcomes after Treating Acute Coronary Syndrome Patients with a Drug-Eluting Stent: Results from REWARDS-EMI (Endeavor® for Myocardial Infarction Registry). Cardiovascular Revascularization Medicine, 2013, 14, 128-133.	0.8	7
530	Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System. Journal of the American College of Cardiology, 2013, 61, 1571-1576.	2.8	55
531	Drug-eluting Stents: Will the transformation to bioabsorption make durable polymers obsolete?. Cardiovascular Revascularization Medicine, 2013, 14, 69-70.	0.8	2
532	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	1.7	160
533	Prevalence and Effect of Myocardial Injury After Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2013, 111, 1337-1343.	1.6	55
534	The state of the excimer laser for coronary intervention in the drug-eluting stent era. Cardiovascular Revascularization Medicine, 2013, 14, 93-98.	0.8	53
535	Prognostic implications of percutaneous coronary interventions performed according to the appropriate use criteria for coronary revascularization. Cardiovascular Revascularization Medicine, 2013, 14, 316-320.	0.8	11
536	Reply. Journal of the American College of Cardiology, 2013, 62, 164-165.	2.8	0
537	Red cell distribution width as a bleeding predictor after percutaneous coronary intervention. American Heart Journal, 2013, 166, 104-109.	2.7	29
538	Safety and Efficacy of Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Women. American Journal of Cardiology, 2013, 111, 21-25.	1.6	3
539	Safety and Efficacy Outcomes of Overlapping Second-Generation Everolimus-Eluting Stents Versus First-Generation Drug-Eluting Stents. American Journal of Cardiology, 2013, 112, 1093-1098.	1.6	26
540	Prednisone: the last gasp of immunosuppresive therapy for restenosis prevention. European Heart Journal, 2013, 34, 1702-1704.	2.2	0

#	Article	IF	CITATIONS
541	Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin. Evidence-Based Medicine, 2013, 18, e30-e30.	0.6	0
542	Serial Observation of Drug-Eluting Absorbable Metal Scaffold. Circulation: Cardiovascular Interventions, 2013, 6, 644-653.	3.9	26
543	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	6.0	194
544	Optimal Revascularization Strategies for Percutaneous Coronary Intervention of Distal Anastomotic Lesions after Coronary Artery Bypass Surgery. Journal of Interventional Cardiology, 2013, 26, 366-371.	1.2	2
545	Acute closure after stenting. Catheterization and Cardiovascular Interventions, 2013, 82, 765-767.	1.7	1
546	Tips and tricks of the CART technique. , 2013, , 198-205.		0
547	Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy. Catheterization and Cardiovascular Interventions, 2013, 82, 614-620.	1.7	1
548	Distal anastomotic lesions after coronary artery bypass surgery: Incidence, pathogenesis, and treatment approach. Catheterization and Cardiovascular Interventions, 2013, 81, 1162-1168.	1.7	1
549	The independent value of a direct stenting strategy on early and late clinical outcomes in patients undergoing elective percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 81, 949-956.	1.7	1
550	Ischemic colitis after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2013, 81, 1067-1071.	1.7	1
551	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	1.7	87
552	Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model. EuroIntervention, 2013, 8, 1441-1450.	3.2	84
553	Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. EuroIntervention, 2013, 8, 1006-1011.	3.2	78
554	Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention, 2013, 9, 613-619.	3.2	79
555	Beta radiation for renal nerve denervation: initial feasibility and safety. EuroIntervention, 2013, 9, 738-744.	3.2	18
556	Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIENâ,,¢ Transcatheter Heart Valve. Circulation, 2012, 125, 550-555.	1.6	26
557	Clinical Outcomes and Treatment After Drug-Eluting Stent Failure. Circulation: Cardiovascular Interventions, 2012, 5, 12-19.	3.9	22
558	Response to Letter by Weimar and Knipp Regarding Article, "Patients With Severe Asymptomatic Carotid Artery Stenosis Do Not Have a Higher Risk of Stroke and Mortality After Coronary Artery Bypass Surgery― Stroke, 2012, 43, .	2.0	0

#	Article	IF	CITATIONS
559	Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. American Heart Journal, 2012, 163, 1031-1036.	2.7	131
560	Hypothermia Therapy. Journal of the American College of Cardiology, 2012, 59, 197-210.	2.8	100
561	Chronic Total Occlusion Recanalization. JACC: Cardiovascular Interventions, 2012, 5, 116-117.	2.9	1
562	Paclitaxel Drug-Coated Balloons. JACC: Cardiovascular Interventions, 2012, 5, 1001-1012.	2.9	81
563	The Appropriate Use of Risk ScoresâŽâŽEditorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology JACC: Cardiovascular Interventions, 2012, 5, 1106-1107.	2.9	1
564	Outcomes of Patients With Severe Aortic Stenosis at High Surgical Risk Evaluated in a Trial of Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2012, 110, 1008-1014.	1.6	21
565	Percutaneous Coronary Intervention With Second-Generation Paclitaxel-Eluting Stents Versus Everolimus-Eluting Stents in United States Contemporary Practice (REWARDS TLX Trial). American Journal of Cardiology, 2012, 110, 1119-1124.	1.6	11
566	Transcatheter aortic valve replacement under monitored anesthesia care versus general anesthesia with intubation. Cardiovascular Revascularization Medicine, 2012, 13, 207-210.	0.8	57
567	Utilization of intravascular ultrasound to accurately position stents in true aorto-ostial lesions. Cardiovascular Revascularization Medicine, 2012, 13, 353-356.	0.8	2
568	Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® Drug-Eluting peripheral stent. Cardiovascular Revascularization Medicine, 2012, 13, 281-285.	0.8	5
569	Back to atheroablation: renaissance or déjà vu?. Cardiovascular Revascularization Medicine, 2012, 13, 205-206.	0.8	0
570	The impact of intra-aortic balloon counter-pulsation on in-hospital mortality in patients presenting with anterior ST-elevation myocardial infarction without cardiogenic shock. Cardiovascular Revascularization Medicine, 2012, 13, 328-330.	0.8	12
571	Qualitative comparison of coronary angiograms between 4 french catheters with an Advanced Cardiovascular Injection System and 6 french catheters with manual injection. Catheterization and Cardiovascular Interventions, 2012, 79, 843-848.	1.7	4
572	Retroperitoneal hemorrhage after percutaneous coronary intervention in the current practice era: Clinical outcomes and prognostic value of abdominal/pelvic computed tomography. Catheterization and Cardiovascular Interventions, 2012, 80, 29-36.	1.7	22
573	A novel, minimally invasive access technique versus standard 18â€gauge needle set for femoral access. Catheterization and Cardiovascular Interventions, 2012, 79, 1180-1185.	1.7	39
574	In vivo comparison of a polymerâ€free Biolimus A9â€eluting stent with a biodegradable polymerâ€based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. Catheterization and Cardiovascular Interventions, 2012, 80, 429-436.	1.7	14
575	Impact of Diabetes Mellitus on Longâ€ŧerm Clinical Outcomes of Patients on Chronic Hemodialysis after Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2012, 25, 147-155.	1.2	8
576	Bifurcation stenting: the current state of play. Cardiovascular Revascularization Medicine, 2012, 13, 51-57.	0.8	0

#	Article	IF	CITATIONS
577	Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Cardiovascular Revascularization Medicine, 2012, 13, 72-74.	0.8	Ο
578	Giant saphenous vein graft aneurysm treated with covered stent. Cardiovascular Revascularization Medicine, 2012, 13, e1-e2.	0.8	2
579	Fluoroscopy use and left anterior descending artery angiography to guide transapical access in patients with prior cardiac surgery. Cardiovascular Revascularization Medicine, 2012, 13, 106-110.	0.8	2
580	Clinical and silent stroke following aortic valve surgery and transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2012, 13, 133-140.	0.8	18
581	Intravascular ultrasound lumen area parameters for assessment of physiological ischemia by fractional flow reserve in intermediate coronary artery stenosis. Cardiovascular Revascularization Medicine, 2012, 13, 177-182.	0.8	49
582	Rebuttal to: Inappropriate use of risk score models for operative mortality in nonsurgical treatments by Luc Noyez, MD, PhD. Cardiovascular Revascularization Medicine, 2012, 13, 184.	0.8	0
583	CRT 2012 welcomed former President Bill Clinton. Cardiovascular Revascularization Medicine, 2012, 13, 75-76.	0.8	Ο
584	Too Early to Call. Cardiovascular Revascularization Medicine, 2012, 13, 157-158.	0.8	3
585	Comparison of Outcome of Higher Versus Lower Transvalvular Gradients in Patients With Severe Aortic Stenosis and Low (<40%) Left Ventricular Ejection Fraction. American Journal of Cardiology, 2012, 109, 1031-1037.	1.6	35
586	Safety and Efficacy of the XIENCE V Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice. American Journal of Cardiology, 2012, 109, 1288-1294.	1.6	30
587	Saphenous Vein Graft Intervention. JACC: Cardiovascular Interventions, 2011, 4, 831-843.	2.9	116
588	Polymer drug-eluting stents: is the future biodegradable?. Lancet, The, 2011, 378, 1900-1902.	13.7	11
589	Cellular Video-Phone Assisted Transmission and Interpretation of Prehospital 12-Lead Electrocardiogram in Acute ST-Segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2011, 24, 112-118.	1.2	11
590	Integrilin in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2011, 24, 351-356.	1.2	13
591	Clinical Profile, Prognostic Implication, and Response to Treatment of Pulmonary Hypertension in Patients With Severe Aortic Stenosis. American Journal of Cardiology, 2011, 107, 1046-1051.	1.6	111
592	Changes in Mitral Regurgitation After Balloon Aortic Valvuloplasty. American Journal of Cardiology, 2011, 108, 1777-1782.	1.6	14
593	Platelet reactivity in diabetic patients subjected to acute exercise stress test. Cardiovascular Revascularization Medicine, 2011, 12, 20-24.	0.8	3
594	The use of excimer laser for complex coronary artery lesions. Cardiovascular Revascularization Medicine, 2011, 12, 69.e1-69.e8.	0.8	25

#	Article	IF	CITATIONS
595	Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovascular Revascularization Medicine, 2011, 12, 312-322.	0.8	40
596	Editorial Note. Cardiovascular Revascularization Medicine, 2011, 12, 1.	0.8	12
597	Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovascular Revascularization Medicine, 2011, 12, 385-390.	0.8	5
598	Editorial Note. Cardiovascular Revascularization Medicine, 2011, 12, 73-74.	0.8	2
599	Comparison between Society of Thoracic Surgeons Score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2011, 12, 345-349.	0.8	75
600	First in the US: can early cardiovascular device evaluation be revived in the US?. Cardiovascular Revascularization Medicine, 2011, 12, 195-196.	0.8	1
601	Winners and losers from the cessation of the Cypher and Nevo stent programs. Cardiovascular Revascularization Medicine, 2011, 12, 269-270.	0.8	Ο
602	From TAVI to TAVR: transforming imagination into reality. Cardiovascular Revascularization Medicine, 2011, 12, 343-344.	0.8	4
603	Outcomes of patients with acute myocardial infarction rom a saphenous vein graft culprit undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2011, 78, 23-29.	1.7	27
604	Comparison of closure strategies after balloon aortic valvuloplasty: Suture mediated versus collagen based versus manual. Catheterization and Cardiovascular Interventions, 2011, 78, 119-124.	1.7	24
605	Covered stents for coronary perforations. Catheterization and Cardiovascular Interventions, 2011, 78, 246-253.	1.7	52
606	Current status, challenges and future directions of drug-eluting balloons. Future Cardiology, 2011, 7, 765-774.	1.2	9
607	Correlation between fractional flow reserve and intravascular ultrasound lumen area in intermediate coronary artery stenosis. EuroIntervention, 2011, 7, 225-233.	3.2	69
608	The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention, 2011, 7, 705-710.	3.2	75
609	In vivo virtual histology intravascular ultrasound comparison of neointimal hyperplasia within drug-eluting- versus bare metal stents. Journal of Invasive Cardiology, 2011, 23, 262-8.	0.4	5
610	Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2010, 75, 86-92.	1.7	27
611	Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?. Circulation, 2010, 122, 1085-1090.	1.6	46
612	Outcome of Undersized Drug-Eluting Stents for Percutaneous Coronary Intervention of Saphenous Vein Graft Lesions. American Journal of Cardiology, 2010, 105, 179-185.	1.6	54

#	Article	IF	CITATIONS
613	Safety and In-Hospital Outcomes of Bivalirudin Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 105, 297-301.	1.6	17
614	Clinical Profile, Treatment Assignment and Clinical Outcome of Patients With Severe Aortic Stenosis Not Eligible to Participate in a Clinical Trial of Percutaneous Aortic Valve Replacement. American Journal of Cardiology, 2010, 105, 857-861.	1.6	6
615	Three-Year Outcomes Following Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). American Journal of Cardiology, 2010, 106, 504-510.	1.6	14
616	A Novel Percutaneous Coronary Intervention Risk Score to Predict One-Year Mortality. American Journal of Cardiology, 2010, 106, 641-645.	1.6	8
617	Correlates and Consequences of Gastrointestinal Bleeding Complicating Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 106, 1069-1074.	1.6	19
618	Patient selection—risk assessment and anatomical selection criteria for patients undergoing transfemoral aortic valve implantation. Cardiovascular Revascularization Medicine, 2010, 11, 124-136.	0.8	15
619	Editorial Note. Cardiovascular Revascularization Medicine, 2010, 11, 139.	0.8	0
620	Editorial Note. Cardiovascular Revascularization Medicine, 2010, 11, 217.	0.8	0
621	A further word of caution before using the internal mammary artery for coronary revascularization in patients with severe peripheral vascular disease!. Catheterization and Cardiovascular Interventions, 2010, 75, 195-201.	1.7	10
622	Combined mechanical and pharmacological approach to a thrombus ontaining lesion. Catheterization and Cardiovascular Interventions, 2010, 75, 972-976.	1.7	2
623	Does on†versus offâ€hours presentation impact inâ€hospital outcomes of STâ€segment elevation myocardial infarction patients transferred to a tertiary care center?. Catheterization and Cardiovascular Interventions, 2010, 76, 484-490.	1.7	10
624	Complications and Outcome of Balloon Aortic Valvuloplasty in High-Risk or Inoperable Patients. JACC: Cardiovascular Interventions, 2010, 3, 1150-1156.	2.9	237
625	Correlates and Causes of Death in Patients With Severe Symptomatic Aortic Stenosis Who Are Not Eligible to Participate in a Clinical Trial of Transcatheter Aortic Valve Implantation. Circulation, 2010, 122, S37-42.	1.6	100
626	Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors. European Heart Journal, 2010, 31, 1079-1087.	2.2	43
627	Biodegradable and Bioabsorbable Stents. Current Pharmaceutical Design, 2010, 16, 4041-4051.	1.9	60
628	Drug-Eluting Stents: Issues of Late Stent Thrombosis. Cardiology Clinics, 2010, 28, 97-105.	2.2	24
629	Synergistic increase risk of death and myocardial infarction at one year in patients with concomitant diabetes mellitus and renal failure. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2010, 4, 190-196.	3.6	0
630	A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 55, 2727-2735.	2.8	202

#	Article	IF	CITATIONS
631	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology, 2010, 56, 919-933.	2.8	1,058
632	Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. American Heart Journal, 2010, 159, 871-875.	2.7	51
633	Body mass index and bleeding complications after percutaneous coronary intervention: Does bivalirudin make a difference?. American Heart Journal, 2010, 159, 1139-1146.	2.7	35
634	Novel antiplatelet therapy. American Heart Journal, 2010, 160, 595-604.	2.7	19
635	Drug-Eluting Balloon. Circulation: Cardiovascular Interventions, 2009, 2, 352-358.	3.9	128
636	Outcome Differences With the Use of Drug-Eluting Stents for the Treatment of In-Stent Restenosis of Bare-Metal Stents Versus Drug-Eluting Stents. American Journal of Cardiology, 2009, 103, 491-495.	1.6	90
637	Prognostic Significance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. American Journal of Cardiology, 2009, 103, 639-645.	1.6	36
638	Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation. American Journal of Cardiology, 2009, 103, 801-805.	1.6	61
639	Incidence, Predictors, and Outcome of New, Subsequent Lesions Treated With Percutaneous Coronary Intervention in Patients Presenting With Myocardial Infarction. American Journal of Cardiology, 2009, 103, 1189-1195.	1.6	17
640	Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. American Journal of Cardiology, 2009, 104, 525-530.	1.6	54
641	Effects of Percutaneous Aortic Valve Replacement on Coronary Blood Flow Assessed With Transesophageal Doppler Echocardiography in Patients With Severe Aortic Stenosis. American Journal of Cardiology, 2009, 104, 850-855.	1.6	16
642	Definition, Incidence, Correlates, and Clinical Impact of "Nuisance―Bleeding in Patients Undergoing Drug-Eluting Stent Implantation. American Journal of Cardiology, 2009, 104, 30C-33C.	1.6	5
643	Effect of Drug-Eluting Stents on Frequency of Repeat Revascularization in Patients With Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2009, 104, 1654-1659.	1.6	15
644	The predictive value of computed tomography calcium scores: a comparison with quantitative volumetric intravascular ultrasound. Cardiovascular Revascularization Medicine, 2009, 10, 30-35.	0.8	9
645	Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovascular Revascularization Medicine, 2009, 10, 156-161.	0.8	18
646	Effects of exogenous peripheral-blood-derived endothelial progenitor cells or unfractionated bone-marrow-derived cells on neointimal formation and inflammation in cholesterol-fed, balloon-denuded, and radiated iliac arteries of inbred rabbits. Cardiovascular Revascularization Medicine, 2009, 10, 110-116.	0.8	5
647	Prognostic value of the syntax score in patients undergoing coronary artery bypass grafting for threeâ€vessel coronary artery disease. Catheterization and Cardiovascular Interventions, 2009, 73, 612-617.	1.7	52
648	Paclitaxelâ€eluting balloon: From bench to bed. Catheterization and Cardiovascular Interventions, 2009, 73, 643-652.	1.7	58

#	Article	IF	CITATIONS
649	Impact of bivalirudin on inâ€hospital bleeding and sixâ€month outcomes in octogenarians undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2009, 74, 428-435.	1.7	19
650	Attenuated Plaque Detected by Intravascular Ultrasound. JACC: Cardiovascular Interventions, 2009, 2, 65-72.	2.9	117
651	Impact of Bivalirudin Use on Outcomes in Nonagenarians Undergoing Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2009, 22, 61-67.	1.2	10
652	Clinical Manifestation and Prognosis of Early versus Late Stent Thrombosis of Drugâ€Eluting Stents. Journal of Interventional Cardiology, 2009, 22, 228-233.	1.2	10
653	Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries. JACC: Cardiovascular Interventions, 2009, 2, 312-320.	2.9	170
654	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 3198-3206.	1.6	794
655	Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. American Heart Journal, 2009, 157, 894-898.	2.7	12
656	Response to "Myocardial infarction in saphenous percutaneous intervention: Are we really doing our best?". American Heart Journal, 2009, 158, e41.	2.7	0
657	The clinical significance of hematocrit values before and after percutaneous coronary intervention. American Heart Journal, 2009, 158, 1024-1030.	2.7	22
658	Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice. Archives of Cardiovascular Diseases, 2009, 102, 143-151.	1.6	12
659	Disease Progression in Nonintervened Saphenous Vein Graft Segments. Journal of the American College of Cardiology, 2009, 53, 1257-1264.	2.8	18
660	Current state of the absorbable metallic (magnesium) stent. EuroIntervention, 2009, 5, F94-F97.	3.2	20
661	Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. EuroIntervention, 2009, 5, F36-F42.	3.2	11
662	Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention, 2009, 4, 481-484.	3.2	61
663	The 5 Ts of Bifurcation Intervention: Type, Technique, Two Stents, T-Stenting, Trials. JACC: Cardiovascular Interventions, 2008, 1, 366-368.	2.9	12
664	Can direct stenting in selected saphenous vein graft lesions be considered an alternative to percutaneous intervention with a distal protection device?. Catheterization and Cardiovascular Interventions, 2008, 72, 799-803.	1.7	24
665	Shortâ€Term Effects of Biocorrodible Iron Stents in Porcine Coronary Arteries. Journal of Interventional Cardiology, 2008, 21, 15-20.	1.2	211
666	Effect of Clopidogrel on Neointimal Formation and Inflammation in Balloonâ€Denuded and Radiated Hypercholesterolemic Rabbit Iliac Arteries. Journal of Interventional Cardiology, 2008, 21, 122-128.	1.2	15

#	Article	IF	CITATIONS
667	Vascular Brachytherapy for Patients with Drugâ€Eluting Stent Restenosis. Journal of Interventional Cardiology, 2008, 21, 528-534.	1.2	15
668	Outcomes After Sirolimus- and Paclitaxel-Eluting Stent Implantation in Patients With Insulin-Treated Diabetes Mellitus. American Journal of Cardiology, 2008, 101, 1253-1258.	1.6	19
669	Incidence, Predictors, and Outcomes of Post-Percutaneous Coronary Intervention Nephropathy in Patients With Diabetes Mellitus and Normal Baseline Serum Creatinine Levels. American Journal of Cardiology, 2008, 101, 1544-1549.	1.6	27
670	Bleeding Risk and Outcomes of Bivalirudin Versus Glycoprotein IIb/IIIa Inhibitors With Targeted Low-Dose Unfractionated Heparin in Patients Having Percutaneous Coronary Intervention for Either Stable or Unstable Angina Pectoris. American Journal of Cardiology, 2008, 102, 160-164.	1.6	20
671	Bivalirudin With Provisional Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Angioplasty in the Setting of Cardiogenic Shock. American Journal of Cardiology, 2008, 102, 287-291.	1.6	21
672	Two-Year Outcome of Patients Treated With Sirolimus- Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). American Journal of Cardiology, 2008, 102, 292-297.	1.6	13
673	Observations and Outcomes of Definite and Probable Drug-Eluting Stent Thrombosis Seen at a Single Hospital in a Four-Year Period. American Journal of Cardiology, 2008, 102, 298-303.	1.6	48
674	Impact of Optimal Medical Therapy and Revascularization on Outcome of Patients With Chronic Kidney Disease and on Dialysis Who Presented With Acute Coronary Syndrome. American Journal of Cardiology, 2008, 102, 535-540.	1.6	40
675	Drug-Eluting Stents Versus Bare Metal Stents for Narrowing in Saphenous Vein Grafts. American Journal of Cardiology, 2008, 102, 530-534.	1.6	42
676	Comparison of Safety, Efficacy, and Outcome of Successful Versus Unsuccessful Percutaneous Coronary Intervention in "True―Chronic Total Occlusions. American Journal of Cardiology, 2008, 102, 1175-1181.	1.6	64
677	Impact of "Nuisance―Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. American Journal of Cardiology, 2008, 102, 1614-1617.	1.6	121
678	Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovascular Revascularization Medicine, 2008, 9, 24-28.	0.8	17
679	Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. Cardiovascular Revascularization Medicine, 2008, 9, 248-254.	0.8	63
680	PhotoPoint Photodynamic Therapy Promotes Stabilization of Atherosclerotic Plaques and Inhibits Plaque Progression. Journal of the American College of Cardiology, 2008, 52, 1024-1032.	2.8	70
681	Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. Archives of Cardiovascular Diseases, 2008, 101, 769-777.	1.6	49
682	Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. International Journal of Cardiology, 2008, 125, 11-15.	1.7	19
683	Drug-eluting stents: is new necessarily better?. Lancet, The, 2008, 372, 1126-1128.	13.7	5
684	The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. European Heart Journal, 2008, 29, 1851-1857.	2.2	265

#	Article	IF	CITATIONS
685	Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent. Circulation, 2008, 117, 1603-1608.	1.6	23
686	Drug-Eluting Stents in Preclinical Studies. Circulation: Cardiovascular Interventions, 2008, 1, 143-153.	3.9	197
687	Intracoronary brachytherapy. , 2008, , 197-217.		1
688	Drug-Eluting Stent Thrombosis vs Bare Metal Stent Restenosis: Finding the Lesser of Two Evils. The American Heart Hospital Journal, 2007, 5, 151-154.	0.2	1
689	Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease. Circulation, 2007, 116, I200-6.	1.6	134
690	Cell therapy in myocardial infarction. Cardiovascular Revascularization Medicine, 2007, 8, 43-51.	0.8	32
691	ACUITY-PCI: one drug does not fit all. Lancet, The, 2007, 369, 881-882.	13.7	20
692	Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, The, 2007, 369, 1869-1875.	13.7	803
693	Brachytherapy. , 2007, , 307-332.		1
694	Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheterization and Cardiovascular Interventions, 2007, 70, 9-14.	1.7	53
695	Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets. Catheterization and Cardiovascular Interventions, 2007, 70, 167-172.	1.7	8
696	Promise and challenges of bioabsorbable stents. Catheterization and Cardiovascular Interventions, 2007, 70, 407-414.	1.7	66
697	Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheterization and Cardiovascular Interventions, 2007, 69, 1064-1074.	1.7	62
698	Does creatine kinase-MB (CK-MB) isoenzyme elevation following percutaneous coronary intervention with drug-eluting stents impact late clinical outcome?. Catheterization and Cardiovascular Interventions, 2007, 70, 826-831.	1.7	8
699	Late stent thrombosis—The "vulnerable―stent. Catheterization and Cardiovascular Interventions, 2007, 70, 54-56.	1.7	4
700	Efficacy and Safety of Absorbable Metallic Stents with Adjunct Intracoronary Beta Radiation in Porcine Coronary Arteries. Journal of Interventional Cardiology, 2007, 20, 367-372.	1.2	31
701	Angiographic and Procedural Correlates of Stent Thrombosis after Intracoronary Implantation of Drug-Eluting Stents. Journal of Interventional Cardiology, 2007, 20, 307-313.	1.2	30
702	Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. Cardiovascular Revascularization Medicine, 2007, 8, 259-274.	0.8	9

#	Article	IF	CITATIONS
703	Comparison of Effectiveness of Bare Metal Stents Versus Drug-Eluting Stents in Large (≥3.5 mm) Coronary Arteries. American Journal of Cardiology, 2007, 99, 599-602.	1.6	55
704	Long-Term Clinical Outcomes and Thrombosis Rates of Sirolimus-Eluting Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (REWARDS Registry). American Journal of Cardiology, 2007, 100, 45-51.	1.6	59
705	Intravascular Ultrasound Parameters Associated With Stent Thrombosis After Drug-Eluting Stent Deployment. American Journal of Cardiology, 2007, 100, 615-620.	1.6	154
706	Impact of In-Stent Restenosis on Death and Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1109-1113.	1.6	20
707	Introduction. American Journal of Cardiology, 2007, 100, S1-S2.	1.6	Ο
708	Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-finding Study. Clinical Cardiology, 2007, 30, 165-170.	1.8	81
709	Role of systemic antirestenotic drugs and results of current clinical trials. , 2007, , 185-194.		0
710	Stenting the vulnerable plaque. , 2007, , 437-443.		0
711	Comparative intravascular ultrasound analysis of ostial disease in the left main versus the right coronary artery. Journal of Invasive Cardiology, 2007, 19, 377-80.	0.4	10
712	IVUS-based dosimetry on patients with repeat-radiated coronary arteries to the same site. Cardiovascular Revascularization Medicine, 2006, 7, 70-75.	0.8	0
713	Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovascular Revascularization Medicine, 2006, 7, 132-135.	0.8	11
714	Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovascular Revascularization Medicine, 2006, 7, 179-184.	0.8	23
715	Bone marrow-derived stem cell interactions with adult cardiomyocytes and skeletal myoblasts in vitro. Cardiovascular Revascularization Medicine, 2006, 7, 222-230.	0.8	13
716	Comparison of paclitaxel-eluting stent and sirolimus-eluting stent expansion at incremental delivery pressures. Cardiovascular Revascularization Medicine, 2006, 7, 208-211.	0.8	21
717	Peroxisome Proliferator-Activated Receptor Î ³ Ligand Pioglitazone Alters Neointimal Composition in a Balloon-Denuded and Radiated Hypercholesterolemic Rabbit. Journal of Cardiovascular Pharmacology, 2006, 48, 299-305.	1.9	22
718	Efficacy of Sirolimus-Eluting Stents as Compared to Paclitaxel-Eluting Stents for Saphenous Vein Graft Intervention. Journal of Interventional Cardiology, 2006, 19, 121-125.	1.2	25
719	Update on Bioabsorbable Stents: From Bench to Clinical. Journal of Interventional Cardiology, 2006, 19, 414-421.	1.2	84
720	Efficacy of Sirolimus-Eluting Stents Compared With Bare Metal Stents for Saphenous Vein Graft Intervention. American Journal of Cardiology, 2006, 97, 34-37.	1.6	77

#	Article	IF	CITATIONS
721	Impact of Three or More Versus a Single Sirolimus-Eluting Stent on Outcomes in Patients Who Undergo Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 606-610.	1.6	13
722	Safety and Feasibility of Transendocardial Autologous Bone Marrow Cell Transplantation in Patients With Advanced Heart Disease. American Journal of Cardiology, 2006, 97, 823-829.	1.6	128
723	An Intravascular Ultrasound Analysis of the Mechanisms of Restenosis Comparing Drug-Eluting Stents With Brachytherapy. American Journal of Cardiology, 2006, 97, 1292-1298.	1.6	23
724	Comparison of Effectiveness and Safety of Drug-Eluting Stents Versus Vascular Brachytherapy for Saphenous Vein Graft In-Stent Restenosis. American Journal of Cardiology, 2006, 97, 1303-1307.	1.6	13
725	Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in the Treatment of Coronary Artery Disease in Patients With Diabetes Mellitus. American Journal of Cardiology, 2006, 98, 187-192.	1.6	38
726	Procedural Results and Outcomes After Extensive Stent Coverage With Drug-Eluting Stent Implantation in Single Coronary Lesions. American Journal of Cardiology, 2006, 98, 357-361.	1.6	4
727	Comparison of Outcomes Between Bare Metal Stents and Drug-Eluting Stents for Percutaneous Revascularization of Internal Mammary Grafts. American Journal of Cardiology, 2006, 98, 722-724.	1.6	19
728	Impact of Low High-Density Lipoproteins on In-Hospital Events and One-Year Clinical Outcomes in Patients With Non–ST-Elevation Myocardial Infarction Acute Coronary Syndrome Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2006, 98, 711-717.	1.6	72
729	Management and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 98, 911-914.	1.6	169
730	Intravascular Brachytherapy Versus Drug-Eluting Stents for the Treatment of Patients With Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2006, 98, 1340-1344.	1.6	61
731	Comparison of Clinical Outcomes of Overlapping Sirolimus- Versus Paclitaxel-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 98, 1563-1566.	1.6	12
732	Sirolimus-eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy. Catheterization and Cardiovascular Interventions, 2006, 68, 873-878.	1.7	92
733	Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 67, 595-599.	1.7	21
734	A novel paclitaxel-eluting porous carbon–carbon nanoparticle coated, nonpolymeric cobalt–chromium stent: Evaluation in a porcine model. Catheterization and Cardiovascular Interventions, 2006, 67, 698-702.	1.7	64
735	Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheterization and Cardiovascular Interventions, 2006, 68, 607-617.	1.7	287
736	Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 68, 62-66.	1.7	3
737	Percutaneous coronary intervention with drug-eluting stents in octogenarians: Characteristics, clinical presentation, and outcomes. Catheterization and Cardiovascular Interventions, 2006, 68, 36-43.	1.7	41
738	Response to Letter Regarding Article, "Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis with Sirolimus- and Paclitaxel-Eluting Stents― Circulation, 2006, 114, .	1.6	0

#	Article	IF	CITATIONS
739	Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents. Circulation, 2006, 113, 1108-1113.	1.6	585
740	Biodegradable stents: they do their job and disappear. Journal of Invasive Cardiology, 2006, 18, 70-4.	0.4	92
741	Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. Journal of Invasive Cardiology, 2006, 18, 273-7.	0.4	47
742	Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH–a multicenter clinical trial. Journal of Invasive Cardiology, 2006, 18, 370-5.	0.4	15
743	Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice. Journal of Cardiovascular Pharmacology, 2005, 46, 481-486.	1.9	96
744	Impact of Treatment of Coronary Artery Disease With Sirolimus-Eluting Stents on Outcomes of Diabetic and Nondiabetic Patients. American Journal of Cardiology, 2005, 96, 1100-1106.	1.6	24
745	Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials. Catheterization and Cardiovascular Interventions, 2005, 64, 61-66.	1.7	1
746	Underexpansion of sirolimus-eluting stents: Incidence and relationship to delivery pressure. Catheterization and Cardiovascular Interventions, 2005, 65, 222-226.	1.7	45
747	Three-year follow-up after intravascular Î ³ -radiation for in-stent restenosis in saphenous vein grafts. Catheterization and Cardiovascular Interventions, 2005, 65, 257-262.	1.7	5
748	Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheterization and Cardiovascular Interventions, 2005, 65, 469-472.	1.7	24
749	Mysteries behind stent struts. Catheterization and Cardiovascular Interventions, 2005, 65, 254-256.	1.7	Ο
750	Selective versus exclusive use of sirolimus-eluting stent implantation in multivessel coronary artery disease. Catheterization and Cardiovascular Interventions, 2005, 65, 473-477.	1.7	5
751	Contemporary use of drug-eluting stents. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 35-46.	0.9	7
752	Effect of Antioxidants on Atherosclerotic Plaque Formation in Balloon-Denuded and Irradiated Hypercholesterolemic Rabbits. Journal of Cardiovascular Pharmacology, 2005, 46, 540-547.	1.9	19
753	Intracoronary radiation therapy using a novel beta emitter for in-stent restenosis. Cardiovascular Revascularization Medicine, 2005, 6, 52-57.	0.8	2
754	Drug-eluting stents for the treatment of in-stent restenosis. Cardiovascular Revascularization Medicine, 2005, 6, 38-43.	0.8	14
755	Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis. Cardiovascular Revascularization Medicine, 2005, 6, 108-112.	0.8	10
756	MRI evaluation of a coronary artery perforation. Cardiovascular Revascularization Medicine, 2005, 6, 44-45.	0.8	1

#	Article	IF	CITATIONS
757	Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. Cardiovascular Revascularization Medicine, 2005, 6, 154-159.	0.8	5
758	Impact of vessel calcification on outcomes after coronary stenting. Cardiovascular Revascularization Medicine, 2005, 6, 147-153.	0.8	104
759	Brachytherapy and bivalirudin evaluation study. American Heart Journal, 2005, 150, 832-837.	2.7	6
760	Drug-eluting stents versus repeat vascular brachytherapy for patients with recurrent in-stent restent restenosis after failed intracoronary radiation. Journal of Invasive Cardiology, 2005, 17, 659-62.	0.4	14
761	The Endeavor Stent System: will it be the new kid on the block?Numero uno, first among equals or equal?. EuroIntervention, 2005, 1, 123-4.	3.2	Ο
762	Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications. Circulation, 2004, 110, 2498-2505.	1.6	74
763	Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis. Circulation, 2004, 109, 340-344.	1.6	118
764	Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis. American Journal of Cardiology, 2004, 93, 313-317.	1.6	13
765	Impact of major side branch on periprocedural enzyme elevation and long-term outcome in patients undergoing percutaneous coronary intervention and brachytherapy for in-stent restenosis. American Journal of Cardiology, 2004, 93, 1394-1397.	1.6	3
766	Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. American Journal of Cardiology, 2004, 94, 789-792.	1.6	26
767	Angiographic and clinical outcomes of late total occlusion versus treatment failure without late total occlusion in patients after intracoronary radiation therapy for in-stent restenosis. American Journal of Cardiology, 2004, 94, 1551-1554.	1.6	3
768	Impact of intravascular ultrasound-guided direct stenting on clinical outcome of patients treated for native coronary disease. Cardiovascular Radiation Medicine, 2004, 5, 15-19.	0.6	6
769	Peroxisome proliferator-activated receptor Î ³ . Cardiovascular Radiation Medicine, 2004, 5, 44-48.	0.6	9
770	Effect of ionizing radiation on the stability and performance of the TAXUS Express2 paclitaxel-eluting stent. Cardiovascular Radiation Medicine, 2004, 5, 136-141.	0.6	6
771	Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Cardiovascular Radiation Medicine, 2004, 5, 64-70.	0.6	6
772	"Hybrid―approach for the treatment of a giant left main coronary artery aneurysm. Cardiovascular Radiation Medicine, 2004, 5, 153-154.	0.6	0
773	Transepicardial autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. Cardiovascular Radiation Medicine, 2004, 5, 125-131.	0.6	24
774	Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovascular Radiation Medicine, 2004, 5, 173-176.	0.6	17

#	Article	IF	CITATIONS
775	Effects of gamma radiation on the noninjured and unprotected left main. Catheterization and Cardiovascular Interventions, 2004, 61, 477-481.	1.7	1
776	Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 61, 354-359.	1.7	3
777	Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary ?-radiation: Integrilin WRIST. Catheterization and Cardiovascular Interventions, 2004, 62, 162-166.	1.7	4
778	Bivalirudin-associated intracoronary thrombosis during ?-brachytherapy and its experimental validation in acute swine model. Catheterization and Cardiovascular Interventions, 2004, 62, 209-213.	1.7	5
779	Vascular complications following coronary intervention correlate with long-term cardiac events. Catheterization and Cardiovascular Interventions, 2004, 62, 181-185.	1.7	15
780	Favorable effect of ?-radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 62, 303-307.	1.7	2
781	Impact of radiation dose on late clinical outcome after intracoronary radiation therapy: Three-year follow-up of Long WRIST. Catheterization and Cardiovascular Interventions, 2004, 62, 318-322.	1.7	4
782	Effects of contrast media on porcine bone marrow-derived mononuclear cells and calf myoblast viability and secretion of VEGF and MCP-1. Catheterization and Cardiovascular Interventions, 2004, 62, 476-481.	1.7	0
783	Vascular brachytherapy vs. drug-eluting stents for the treatment of in-stent restenosis: The jury's still out. Catheterization and Cardiovascular Interventions, 2004, 62, 290-291.	1.7	4
784	Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions. Journal of the American College of Cardiology, 2004, 44, 1386-1392.	2.8	28
785	Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis. Drugs, 2004, 64, 2379-2388.	10.9	18
786	Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, The, 2004, 364, 1519-1521.	13.7	1,338
787	Antioxidants attenuate atherosclerotic plaque development in a balloon-denuded and -radiated hypercholesterolemic rabbit. Cardiovascular Radiation Medicine, 2003, 4, 25-28.	0.6	9
788	Acute procedural complications and in-hospital events after percutaneous coronary interventions. Cardiovascular Radiation Medicine, 2003, 4, 12-17.	0.6	5
789	Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovascular Radiation Medicine, 2003, 4, 34-38.	0.6	34
790	Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium. Cardiovascular Radiation Medicine, 2003, 4, 164-168.	0.6	21
791	Beta emitter systems and results from clinical trials. Cardiovascular Radiation Medicine, 2003, 4, 54-63.	0.6	9
792	A case of Cypher restenosis treated with gamma radiation. Cardiovascular Radiation Medicine, 2003, 4, 169-170.	0.6	2

RON WAKSMAN

#	Article	IF	CITATIONS
793	Radiation-Induced Atherosclerotic Plaque Progression in a Hypercholesterolemic Rabbit. Cardiovascular Radiation Medicine, 2003, 4, 146-151.	0.6	33
794	Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin,) Tj ETQq0 0 0 rg intervention. American Journal of Cardiology, 2003, 92, 1080-1083.	3T /Overloo 1.6	ck 10 Tf 50 7 17
795	Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. American Journal of Cardiology, 2003, 92, 1409-1413.	1.6	27
796	Comparison of intracoronary gamma radiation for in-stent restenosis in saphenous vein grafts versus native coronary arteries. American Journal of Cardiology, 2003, 91, 22-26.	1.6	7
797	Usefulness of gamma intracoronary radiation for totally occluded in-stent restenotic coronary narrowing. American Journal of Cardiology, 2003, 91, 595-597.	1.6	5
798	Serial volumetric intravascular ultrasound assessment of native coronary artery versus saphenous vein grafts in-stent restenosis lesions after conventional catheter-based treatment. American Journal of Cardiology, 2003, 91, 739-741.	1.6	2
799	Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition With Beta In-Stent Trial. American Journal of Cardiology, 2003, 91, 1113-1115.	1.6	2
800	Implications of the presence and length of "geographic miss―on restenosis and the edge phenomenon in the INHIBIT trial. American Journal of Cardiology, 2003, 91, 1261-1265.	1.6	7
801	Usefulness of beta radiation for de novo and In-Stent restenotic lesions in saphenous vein grafts. American Journal of Cardiology, 2003, 92, 312-314.	1.6	16
802	Comparison of creatine kinase elevation and outcome of comparison of percutaneous coronary intervention for saphenous vein graft in-stent restenosis versus de novo stenosis. American Journal of Cardiology, 2003, 92, 980-983.	1.6	5
803	Impact of intracoronary radiation on in-stent restenosis involving ostial lesions. Catheterization and Cardiovascular Interventions, 2003, 58, 175-180.	1.7	4
804	Late thrombosis after gamma-brachytherapy. Catheterization and Cardiovascular Interventions, 2003, 58, 455-458.	1.7	11
805	Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis. Catheterization and Cardiovascular Interventions, 2003, 59, 1-5.	1.7	9
806	Percutaneous coronary interventionâ€essociated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheterization and Cardiovascular Interventions, 2003, 59, 338-343.	1.7	145
807	Understanding and Preventing the Edge Effect. Journal of Interventional Cardiology, 2003, 16, 1-7.	1.2	4
808	Late Thrombosis: A Problem Solved. Journal of Interventional Cardiology, 2003, 16, 9-13.	1.2	1
809	Vascular Brachytherapy: Is It Still a Viable Option?. Journal of Vascular and Interventional Radiology, 2003, 14, P79-P83.	0.5	0
810	The outcome of percutaneous coronary intervention in patients with In-Stentrestenosis who failed intracoronary radiation therapy. Journal of the American College of Cardiology, 2003, 41, 551-556.	2.8	22

#	Article	IF	CITATIONS
811	Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. Journal of the American College of Cardiology, 2003, 41, 1725-1731.	2.8	10
812	Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. Journal of the American College of Cardiology, 2003, 41, 1721-1724.	2.8	392
813	Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study. American Heart Journal, 2003, 146, 142-145.	2.7	9
814	Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. American Heart Journal, 2003, 146, 501-506.	2.7	67
815	Coronary Brachytherapy in the Drug-Eluting Stent Era. Circulation, 2003, 108, 386-388.	1.6	24
816	Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions. Circulation, 2003, 107, 1744-1749.	1.6	100
817	Predictors of Subacute Stent Thrombosis. Circulation, 2003, 108, 43-47.	1.6	459
818	Time Course of Stent Endothelialization After Intravascular Radiation Therapy in Rabbit Iliac Arteries. Circulation, 2003, 107, 2153-2158.	1.6	44
819	Repeat Intracoronary Radiation for Recurrent In-Stent Restenosis in Patients Who Failed Intracoronary Radiation. Circulation, 2003, 108, 654-656.	1.6	29
820	Review of intracoronary radiation for in-stent restenosis. Journal of Invasive Cardiology, 2003, 15 Suppl A, 2A-8A.	0.4	2
821	Incidence, Morphology, Angiographic Findings, and Outcomes of Intramural Hematomas After Percutaneous Coronary Interventions. Circulation, 2002, 105, 2037-2042.	1.6	90
822	Radioactive 133-Xenon Gas-Filled Balloon to Prevent Restenosis. Circulation, 2002, 106, 725-729.	1.6	5
823	Twelve Versus Six Months of Clopidogrel to Reduce Major Cardiac Events in Patients Undergoing Î ³ -Radiation Therapy for In-Stent Restenosis. Circulation, 2002, 106, 776-778.	1.6	130
824	Intravascular Gamma Radiation for In-Stent Restenosis in Saphenous-Vein Bypass Grafts. New England Journal of Medicine, 2002, 346, 1194-1199.	27.0	140
825	How to Fix the Edge Effect of Catheter-Based Radiation Therapy in Stented Arteries. Circulation, 2002, 106, 2271-2277.	1.6	26
826	Drug-Eluting Stents in Preclinical Studies. Circulation, 2002, 106, 1867-1873.	1.6	271
827	Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. Journal of the American College of Cardiology, 2002, 39, 274-280.	2.8	115
828	The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox?. Journal of the American College of Cardiology, 2002, 39, 578-584.	2.8	596

#	Article	IF	CITATIONS
829	The impact of lesion length and reference vessel diameter on angiographic restenosis and target vessel revascularization in treating in-stent restenosis with radiation. Journal of the American College of Cardiology, 2002, 39, 1290-1296.	2.8	23
830	The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. Journal of the American College of Cardiology, 2002, 39, 1930-1936.	2.8	41
831	Morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. Journal of the American College of Cardiology, 2002, 40, 904-910.	2.8	333
832	Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet, The, 2002, 359, 551-557.	13.7	291
833	Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. American Journal of Cardiology, 2002, 89, 54-57.	1.6	61
834	Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma) Tj ETQq0 0	0.rgBT /O	verlock 10 T
835	Relation of residual stenosis after angioplasty to long-term outcome of patients treated for in-stent restenosis with intravascular radiation therapy. American Journal of Cardiology, 2002, 89, 1426-1428.	1.6	3
836	Intravascular ultrasound analysis of the impact of gamma radiation therapy on the treatment of saphenous vein graft in-stent restenosis. American Journal of Cardiology, 2002, 90, 1378-1381.	1.6	1
837	Editorial Note 3:1. Cardiovascular Radiation Medicine, 2002, 3, 1.	0.6	3
838	The cost-effectiveness of β-radiation therapy for treatment of in-stent restenosis. Cardiovascular Radiation Medicine, 2002, 3, 107-113.	0.6	4
839	The initial course of in-stent restenosis influences the response to vascular brachytherapy. Cardiovascular Radiation Medicine, 2002, 3, 102-106.	0.6	1
840	The proximal location of stenosis in the left anterior descending coronary artery is not a predictive factor of worse outcome in the era of stent. Cardiovascular Radiation Medicine, 2002, 3, 127-132.	0.6	3
841	Drug-eluting stents. Cardiovascular Radiation Medicine, 2002, 3, 226-241.	0.6	34
842	A case of refractory in-stent restenosis: Failed RE-WRIST. Catheterization and Cardiovascular Interventions, 2002, 57, 72-74.	1.7	3
843	Elderly patients have a favorable outcome after intracoronary radiation for in-stent restenosis. Catheterization and Cardiovascular Interventions, 2002, 56, 466-471.	1.7	6
844	Balloon-based radiation therapy for treatment of in-stent restenosis in human coronary arteries: Results from the BRITE I study. Catheterization and Cardiovascular Interventions, 2002, 57, 286-294.	1.7	14
845	The Wrist Series - What Have We Learnt?. Herz, 2002, 27, 23-29.	1.1	6
846	Localized intracoronary beta radiation therapy to inhibit recurrence of in-stent restenosis. Clinical Research in Cardiology, 2002, 91, 40-41.	1.1	8

#	Article	IF	CITATIONS
847	Effectiveness of radioactive tungsten source in the prevention of restenosis in stented porcine coronary arteries. International Journal of Radiation Oncology Biology Physics, 2002, 54, 252-262.	0.8	2
848	Vascular brachytherapy: applications in the era of drug-eluting stents. Reviews in Cardiovascular Medicine, 2002, 3 Suppl 5, S23-30.	1.4	1
849	Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. Journal of the American College of Cardiology, 2001, 37, 1026-1030.	2.8	77
850	Intravascular Radiation Therapy after Balloon Angioplasty of Narrowed Femoropopliteal Arteries to Prevent Restenosis: Results of the PARIS Feasibility Clinical Trial. Journal of Vascular and Interventional Radiology, 2001, 12, 915-921.	0.5	91
851	Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. American Heart Journal, 2001, 141, 610-614.	2.7	44
852	Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. Expert Opinion on Investigational Drugs, 2001, 10, 891-907.	4.1	21
853	A novel 32 P deployable balloon system inhibits formation of neointima in porcine coronary arteries after balloon-overstretching injury. Coronary Artery Disease, 2001, 12, 317-322.	0.7	3
854	Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2001, 52, 409-416.	1.7	219
855	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheterization and Cardiovascular Interventions, 2001, 54, 295-300.	1.7	25
856	Intracoronary Beta Radiation: State of the Art. Journal of Interventional Cardiology, 2001, 14, 601-609.	1.2	6
857	Delayed re-endothelialization and T-cell infiltration following intracoronary radiation therapy in the porcine model. International Journal of Radiation Oncology Biology Physics, 2001, 50, 495-501.	0.8	10
858	Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions. American Journal of Cardiology, 2001, 87, 1145-1149.	1.6	17
859	Intravascular ultrasound assessment of the stenoses location and morphology in the left main coronary artery in relation to anatomic left main length. American Journal of Cardiology, 2001, 88, 1-4.	1.6	39
860	Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with diffuse in-stent restenosis. American Journal of Cardiology, 2001, 88, 425-428.	1.6	48
861	Differential remodeling after balloon overstretch injury and either β- or γ-intracoronary radiation of porcine coronary arteries. Cardiovascular Radiation Medicine, 2001, 2, 75-82.	0.6	9
862	Clinical trials of vascular brachytherapy for in-stent restenosis: update. Cardiovascular Radiation Medicine, 2001, 2, 107-113.	0.6	30
863	Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. Cardiovascular Radiation Medicine, 2001, 2, 63-68.	0.6	15
864	Excimer laser coronary angioplasty and intracoronary radiation for in-stent restenosis: Six-month angiographic and clinical outcomes. Cardiovascular Radiation Medicine, 2001, 2, 191-196.	0.6	7

#	Article	IF	CITATIONS
865	Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Cardiovascular Radiation Medicine, 2001, 2, 200-204.	0.6	28
866	Intravascular radiation accelerates atherosclerotic lesion formation of hypercholesteremic rabbits. Cardiovascular Radiation Medicine, 2001, 2, 231-240.	0.6	28
867	Edge Stenosis After Intracoronary Radiotherapy. Circulation, 2001, 103, 2219-2220.	1.6	7
868	Comparative Efficacy of Î ³ -Irradiation for Treatment of In-Stent Restenosis in Saphenous Vein Graft Versus Native Coronary Artery In-Stent Restenosis. Circulation, 2001, 104, 3020-3022.	1.6	18
869	Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary γ-Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions. Circulation, 2001, 104, 856-859.	1.6	45
870	Serial Intravascular Ultrasound Analysis of the Impact of Lesion Length on the Efficacy of Intracoronary Î ³ -Irradiation for Preventing Recurrent In-Stent Restenosis. Circulation, 2001, 103, 188-191.	1.6	29
871	Prolonged Antiplatelet Therapy to Prevent Late Thrombosis After Intracoronary γ-Radiation in Patients With In-Stent Restenosis. Circulation, 2001, 103, 2332-2335.	1.6	167
872	Late thrombosis following intracoronary brachytherapy. Catheterization and Cardiovascular Interventions, 2000, 49, 344-347.	1.7	37
873	Late total occlusions following restenting for in-stent restenosis: To restent or not to restent?. Catheterization and Cardiovascular Interventions, 2000, 49, 479b-480.	1.7	0
874	Intracoronary brachytherapy not associated with changes in major side branches. Catheterization and Cardiovascular Interventions, 2000, 51, 154-158.	1.7	4
875	Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention. American Journal of Cardiology, 2000, 86, 680-682.	1.6	161
876	Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. American Journal of Cardiology, 2000, 86, 777-779.	1.6	18
877	Safety of Intracoronary Î ³ -Radiation on Uninjured Reference Segments During the First 6 Months After Treatment of In-Stent Restenosis. Circulation, 2000, 101, 2227-2230.	1.6	24
878	Intracoronary β-Radiation Therapy Inhibits Recurrence of In-Stent Restenosis. Circulation, 2000, 101, 1895-1898.	1.6	304
879	Intracoronary Î ³ -Radiation Therapy After Angioplasty Inhibits Recurrence in Patients With In-Stent Restenosis. Circulation, 2000, 101, 2165-2171.	1.6	517
880	Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy. Circulation, 2000, 101, 2484-2489.	1.6	140
881	β-Radiation to INHIBIT Recurrence of In-Stent Restenosis: Clinical and Angiographic Results of the Multicenter, Randomized, Double-Blind Study. Circulation, 2000, 102, .	1.6	22
882	Positive Remodeling, Regression of In-Stent Neointimal Hyperplasia, and Late Stent Malapposition in the Absence of Brachytherapy. Circulation, 2000, 102, E111.	1.6	3

#	Article	IF	CITATIONS
883	Inhibition of Restenosis With β-Emitting Radiotherapy. Circulation, 2000, 102, 951-958.	1.6	254
884	Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. Journal of the American College of Cardiology, 2000, 36, 65-68.	2.8	216
885	Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. Journal of the American College of Cardiology, 2000, 35, 389-397.	2.8	28
886	Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. Journal of the American College of Cardiology, 2000, 35, 944-948.	2.8	57
887	Late Thrombosis After Radiation. Circulation, 1999, 100, 780-782.	1.6	170
888	Effects of Intracoronary Radiation on Thrombosis After Balloon Overstretch Injury in the Porcine Model. Circulation, 1999, 100, 2527-2533.	1.6	51
889	Fibrocellular tissue responses to endovascular and external beam irradiation in the porcine model of restenosis. International Journal of Radiation Oncology Biology Physics, 1999, 44, 633-641.	0.8	23
890	Vascular Brachytherapy: Are We Ready Yet?. Journal of Interventional Cardiology, 1999, 12, 233-234.	1.2	0
891	Intracoronary Irradiation with186/188Rhenium Following Balloon Overstretch Injury Reduces Neointima But Does Not Impair Vasoreactivity of Porcine Coronary Arteries. Journal of Interventional Cardiology, 1999, 12, 263-270.	1.2	4
892	Vascular Brachytherapy for Prevention of Recurrence of In-stent Restenosis. Journal of Interventional Cardiology, 1999, 12, 305-312.	1.2	3
893	Surface Profile of the Internal Elastic Lamina May Modulate Thrombosis Following Intracoronary Radiation in Balloon-Injured Porcine Arteries. Journal of Interventional Cardiology, 1999, 12, 457-464.	1.2	1
894	Modulation of protein expression and activity by radiation. Cardiovascular Radiation Medicine, 1999, 1, 336-343.	0.6	1
895	Two-year follow-up after intracoronary gamma radiation therapy. Cardiovascular Radiation Medicine, 1999, 1, 30-35.	0.6	27
896	Intracoronary Radiation Post PTCA Prevents Late Arterial Constriction. Journal of Interventional Cardiology, 1998, 11, 535-541.	1.2	4
897	Intracoronary brachytherapy in the cath lab. Herz, 1998, 23, 401-406.	1.1	11
898	Endovascular β-Radiation to Reduce Restenosis After Coronary Balloon Angioplasty. Circulation, 1998, 97, 2025-2030.	1.6	342
899	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. Circulation, 1998, 97, 1355-1361.	1.6	61
900	Short- and long-term outcome of narrowed saphenous vein bypass graft: A comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty. American Heart Journal, 1997, 134, 274-281.	2.7	27

RON WAKSMAN

#	Article	IF	CITATIONS
901	Intracoronary Radiation Adjunct Therapy to Stenting. Journal of Interventional Cardiology, 1997, 10, 133-135.	1.2	1
902	Long-term Angiographic and Clinical Outcome After Percutaneous Transluminal Coronary Angioplasty and Intracoronary Radiation Therapy in Humans. Circulation, 1997, 96, 727-732.	1.6	289
903	Effect of Intravascular Irradiation on Cell Proliferation, Apoptosis, and Vascular Remodeling After Balloon Overstretch Injury of Porcine Coronary Arteries. Circulation, 1997, 96, 1944-1952.	1.6	143
904	Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. American Journal of Cardiology, 1996, 78, 221-224.	1.6	4
905	Myocardial infarction as a complication of new interventional devices. American Journal of Cardiology, 1996, 78, 751-756.	1.6	31
906	The role of the adventitia in the arterial response to angioplasty: The effect of intravascular radiation. International Journal of Radiation Oncology Biology Physics, 1996, 36, 789-796.	0.8	186
907	Predictors of groin complications after balloon and new-device coronary intervention. American Journal of Cardiology, 1995, 75, 886-889.	1.6	194
908	Distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. American Heart Journal, 1995, 129, 430-435.	2.7	13
909	Endovascular Low-Dose Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in Swine. Circulation, 1995, 91, 1533-1539.	1.6	305
910	Intracoronary Low-Dose Î ² -Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in the Swine Restenosis Model. Circulation, 1995, 92, 3025-3031.	1.6	238
911	Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries. Circulation, 1995, 92, 1383-1386.	1.6	157
912	Efficacy and safety of using perfusion dilatation catheter as initial balloon in coronary angioplasty. Catheterization and Cardiovascular Diagnosis, 1994, 32, 319-322.	0.3	2
913	The Pathobiology of CTO. , 0, , 1-7.		1
914	Streptokinase, Alteplase, Reteplase, or Tenecteplase. , 0, , 133-139.		0
915	Bilateral Approach. , 0, , 107-112.		1
916	Other Books Available from Wiley-Blackwell. , 0, , G1-G1.		0
917	Parallel-Wire Techniques. , 0, , 83-86.		2
918	Optimal Antithrombotic Therapy. , 0, , 1-9.		0

#	Article	IF	CITATIONS
919	Antithrombotic Therapy for Non ST-Elevation Acute Coronary Syndromes. , 0, , 79-92.		1
920	Oral Anticoagulation Issues in Percutaneous Coronary Intervention. , 0, , 158-164.		0
921	High-Risk Coronary Intervention and Renal Dysfunction. , 0, , 190-194.		0
922	Ideal Contrast Agent. , 0, , 210-215.		0
923	Clopidogrel Use in Patients Requiring Coronary Artery Bypass Grafting. , 0, , 257-260.		0
924	Introduction of a New 0.014-Inch CiTopâ,,¢ Guidewire for CTO: Preclinical Safety and Feasibility Studies. , 0, , 62-69.		0
925	Frontrunner CTO Technology. , 0, , 70-73.		0
926	Use of Two Wires in the Treatment of CTO. , 0, , 75-82.		0
927	Wire Control Handling Technique. , 0, , 87-92.		0
928	Subintimal Angioplasty. , 0, , 93-103.		0
929	Re-Entry Technique– Pioneer Catheter. , 0, , 104-106.		0
930	Tips and Tricks of the CART Technique. , 0, , 113-120.		0
931	Radio Frequency. , 0, , 121-135.		0
932	Indication and Outcome of PCI for CTO. , 0, , 8-13.		0
933	High-Frequency Mechanical Revascularization. , 0, , 136-139.		0
934	Debulking of CTO. , 0, , 140-144.		0
935	Vibrational Angioplasty. , 0, , 145-149.		0
936	Drug-Eluting Stents. , 0, , 150-158.		0

#	Article	IF	CITATIONS
937	Laser for CTO Recanalization. , 0, , 159-164.		0
938	How to Minimize Contrast Nephropathy. , 0, , 178-185.		0
939	Interesting Cases I, II. , 0, , 187-193.		0
940	CTO– Review of Trials. , 0, , 14-21.		0
941	CT Angiography: Application in Chronic Total Occlusions. , 0, , 23-31.		0
942	Magnetic Navigation Wire. , 0, , 32-37.		0
943	IVUS-Guided Recanalization of CTO. , 0, , 38-41.		0
944	Deflecting Tip Wires. , 0, , 43-49.		0
945	ASAHI Wires. , 0, , 50-56.		0
946	Tornus Catheter. , 0, , 57-61.		0